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ABSTRACT 
The Impact of Federal Regu)ation on 1ime to F.quivalence 
and Comp1~:nce within the Orthopaedic Medicai Device Industry 
The Medica! Device Amendments of 1976 (Public Law 94-295) consolidated and expanded 
existing federal ~mthority over manufacturers of medical devices. This m:ant that any medical 
device manufactured after the Medical Device Amendment of 1976 needed to establish that it is 
substantially equivalent in terms of conten~ composition, intended use and related risk. This study 
was designed to investigate the influences on the process of notifying the Food ~nd Drug 
Administration (FDA) of an orthopaedic medical device manufacturer's intent to market a 
product. The study's primary objective;; w~ twofoirl: i) determine the relationships of three 
independent variables (i.e., the company's su.e and longevity) with the dependent \tariable, time 
to equivalence and 2) compare differences in mean days to equivalen~ based on specified 
company characteristics (i.e., regulatory affairs consultant use, regulatory training experiences, 
in-house regulatory department presence or absence, and attitudes toward influences on timely 
compliance). A survey instrument was returned by the regulatory manager at 39 companies 
representing 263 device equivalen~ submissions and 27 different medical device categories from 
1977 through 1987. Four different statistical approaches were utilized: correlative-regressive, 
comparative, regressive-predictive, and distributive. From ilibi research certain company 
characteristics which impact time to equivalence were identified. It was found that companies who 
have been manufacturing numerous years, manufacture more than one medical device, and use 
regulatory affairs professionals to assist with compliance issues, especially just following the 
e-uactment of a new regulation, may have predictaNv fewer days to equivalence than companies 
that do not possess these characteristics. Statistically significant relationships and differences in 
mean days to equivalence were computed for some variables. 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
DEDICATION 
This research is dedicated to my parents for all they have 
given me and to my son for all I will be able to give him. 
ii 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
ACKNOWLEDGEMENTS 
I would like to express special gratitude to Dr. Susan 
Zgliczynski, my Committee Chairperson, for her guidance, 
encouragement, and patience in the execu~luu oi this research 
endeavor. A very special thought goes out to Dr. Dee Strunk, my 
first Committee Chairperson, who has passed away. 
A grateful acknowledgement is mad~ to Dr. Jerry Ammer and 
Ms. Joyce Bromm, Esq., for their intellectual stimulation and 
encouragement. 
I would also like to express my thanks to Ms. Pamela Buclanan, 
my sister and employer, for her help, encouragement, support, and 
trust. 
Finally, I would like to acknowledge my family and friends for 
their patience, sacrifices, and tolerance during the period of my 
studies. 
iii 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
TABLE OF CONTENTS 
DEDICATION ......•.•... . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ACKNOWLEDGEMENTS •..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
LIST OF FIGtJRES •••••••••••• e e e O O e e e e e e e e e • e • • e • e • • 
LIST OF TABLES ••••••••••••••••••••• . , •••• 0 •••••••• 
LIST OF APPE~-OICES ..• ............................. 
CHAPTER I • INTRODUCTION. 
Statement of Problem . ............... . 
Research Question Number 1 •. ............ 
Research Question Number 2 •• ............ 
Research Question ~·umber 3 •• ............ 
Research Question Number 4. ............. 
Research Question Number 5 • . . . . . . . . . . . . . 
Importance and Relevance •••••••• .......... 























SlllDlllacy • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • i S 
CHAPTER II. REVIEW OF THE LITERATURE ••••••••••• 
Historical Dimension ••• ...................... 
Svcial Regulation. ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ C ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ 
Social Regulation and the 






Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
Page 
Regulated Industry Studies................... 30 
Research Studies............................. 32 
.................................... 
CHAPTER II I. METHODOLOGY. 
Introduction •••••• . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Choice of Method •••• 
Research Population. 
Instrumentation. 
Pilot Study • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Procedures •• . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Questionnaire Mailing. 
Data Collection and Follow-Up. 












Approach I. . . . . . . . . . . . . . • . . . . . . . . . . . . . . . 5:? 




Approach IV. • • • • • • • • • • • • • • • • • • • • • • • • • • • • 54 
Criteria for Data Sources. 
Summary • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 0 •• 
CHAPTER IV. DATA ANALYSIS. ..................... 
Unit of Analysis •••••••• ..................... 
Medical Device Categories. 
Results of Analysis ••••••• 
................... 
................... 
Research Question Number 1. 












Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
Research Question Number 3 • 
Research Question Number 4. 
Research Question Number 5. 
. . . . . . . . . . . . . 
S11:rnrn a :cy • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 
CHAPTER V. SUMMARY AND RECOMMENDATIONS. 
Summ.a:cy • ••••••••••••••••••••••••••••••••••••• 
The Research Problem. 
The Reseaxch Approaches. 
Criteria for Data Sources ••••• 
Review of Selected Literature. 
Method •• .•.••.•••••• 
Collection of Data. 
Analysis of Data ••• 
Findings. 
Conclusions . ............................ . 
Implications for Business and Government. 
Recommendations for Future Research •••••• 
REFERENCES. 
APPENDICES .•..... 
Appendix A •• 
Appendix B •• 
Appendix c •. 
Appendix D •• 
Appendix E •• 

































Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.




Orthopaedic Device Classification Category 
and FDA Device Classification •••••••••••••••• 
Orthopaedic Medical Device Category, Number 
of Companies, and Number of Device 





Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.




Model Relating Variable DAYS TO EQUIVALENCE 
to Variable NUMBER OF YEAR$ MANUFACTURING •••• 
Quadratic Model Relating Variable DAYS TO 
EQUIVALENCE to Variable NUMBER OF YEAR 
MAN""""UFACTtJRING • ••••••••••••••••••••••••••••••• 
3. Model Relating Variable DAYS TO EQUIVALENCE 




THE ORGAN'IZATION. . • . • • • . • • • • • • . • • . • • • • . • • • • • • 67 
4. Model Relating Variable DAYS TO EQUIVALENCE 
to Variable NUMBER OF EMPLOYEES IN 






Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by 
Variable TYPE OF DEVICE •••••••••••••••••••••• 
Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by 
Variable REGULATORY DEPARTMENT ••••••••••••••• 
Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by 
Variable REGULATORY TRAINING ••••••••••••••••• 
Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by Variable 
MORE TllAN ONE DEVICE ••••••••••••••••••••••••• 
Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by Variable 
REGULATORY CONSULTANT USE •••••••.•••••••••••• 
10. Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by Variable 






WITH FDA. • • • • • • • . • • • • • • • • • • • • • • • • • • . • . .. . • • • • . 87 
11. Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by Variable 
ATTITUDE TOWARD ORAL COMMUNICATION WITH FDA.. 89 
12. Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by Variable 
ATTITUDE TOWARD REGULATORY TRAINING.......... 91 
viii 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
Table 
13. Crosstabulation of Variable DAYS TO 
EQUIVALENCE by Variable ATTITUDE TOW~ 
Page 
REGULATORY TRAINING. • • • • • • • • • • • • • • • • • • • • • • • • • 9 2 
14. Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by Variable 
ATTITUDE TOWARD IN-HOUSE REGULATORY 
DEPAR.TMENT. • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 94 
15. Wilcoxon Score (Rank Sums) for Variable 
DAYS TO EQUIVALENCE Classified by Variable 
ATTITUDE TOWARD REGULATORY CONSULTANT USE. • • • 96 
16. Crosstabulation of Variable DAYS TO 
TO EQUIVALENCE by Variable AT'l'ITUDE TOWARD 
REGULATORY CONSULTANT USE.................... 97 
17. Model Relating Variable DAYS TO EQUIVALENCE 
to Multiple Independent Variables •••••••••••• 100 
18. Frequency Distribution of Entities Impacting 
Variable DAYS TO EQUIVALENCE ••••••••••••••••• 105 
ix 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
LIST OF APPENDIXES 
Appendi,c 
Page 
A. Transmittal Letter for Pilot Study ••••••••••• 145 
B. Transmittal Letter for Research •••••••••••••• 146 
c. Survey Questionnaire ••••••••••••••••••••••••• 147 
D. Summary of Research Hypotheses 1.1 - l. 3: Relationships Between Organizational Characteristics and Time to Equivalence •••••• 150 
E. Summary of Research Hypotheses 2.1 - 2.5: Differences in Time to Equivalence Relative to Organizational Characteristics .••••.•••••• 151 
F. Summary of Research Hypotheses 3.1 - 3.Si Differences in Time to Equivalence Relative to Top Executive's Perceived Influences on Timely Regulatory Compliance ••••••••••••••••• 152 
X 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
Time To Equivalence 
CHAPTER I 
INTR0:i::D'CTION 
What do Band-Aids, contact lenses, cardiac pacemakers, and 
magnetic resonance imaging machines have in common? They are all 
medical devices, according to federal law. Judging the safety and 
effectiveness of these four products and over 47,000 other medical 
devices is the job of the Food and Drug Administration (FDA). But 
for a variety of reasons, federal regulation of medical devices is 
beset with major problems. As a result, little information is 
available to determine whether medical devices, which are becoming 
increasingly sophisticated, are safe and work as intended. 
The situation above has forced the FDA~~ reverse ths present 
congressional sentiment of deregulation and, consequently, impose 
more controls upon medical device manufacturers. The number of 
device establishments has exploded to more than 12,000 and every 
one is jockeying for market position. Government requirements are 
a hurdle to new products and better sales. 
Thie study proposes to evaluate the relationships and 
differences between regulatory requirements and time to established 
equivalence or FDA disposition in the orthopaedic medical device 
industry. The concentration in the orthopaedic area in the medical 
device industry was guided by concerns regarding the narrowing of 
Page 1 
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research focus and significance of ultimate research findings. More 
specifically, the process of interpreting regulatory requirements 
and timely submissions in the orthopaedic medical device area is 
the primary aim of this research. The paradigm, •Time is money!", 
is sssantially being examined. The longer a developed product 
remains off the market, the greater the consumption of the 
manufacturer's resources and decreased share of market. 
The degree of market share protection a company can expect 
depends on the rouce chosen by the company to market its product. 
One route is the section 510(k) (Public Law No. 94-295), or the 
premarket notification process (PMAA), of the Federal Food, Drug, 
and Cosmetic Act (FDC Act) (Public Law No. 75-717). Under section 
Sl0(k), a manufacturer is required to file with FDA a premarket 
notification at least ninety days before marketing a class I or 
class II device. The purpose of the 510(k) is to establish that the 
device is substantially equivalent to another device already on the 
market. A 510(k) notification is generally a few pages long and 
usually does not contain clinical data. The FDA's average review 
time for the Sl0(k) is approximately 64 days (FDA Annual Report, 
1988). Although FDA has 90 days to complete the review process, the 
manufacturer must wait for either 90 days or until it is notified 
by FDA of the device's equivalence. 
The PMAA process is the second route to market. The content 
requirements for a PMAA are much more rigorous than the 
Page 2 
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requirements for the SlO(k) notification process. A PMAA is a 
voluminous and detailed submission that usually includes 
preclinical and clinical data. The average review time for a PMAA 
is 142 to 262 days (FDA Annual Report, 1988). 
The scope of this research is limited to gathering data as it 
relates to the SlO(k) process only. 
The SlOlK) Register (Diogenes, 1988) is a document which has 
been published annually since 1976. This is the year in which 
regulatory reform was introduced to the medical device industry. 
All SlO(k)s filed since 1976 are listed in this document. From this 
text can be gleaned the submission dates and the dates when 
equivalence was determined. These days c~n v~r:-i from as few as two 
days to as many as 200 or more. Estimated costs are associated with 
each day that product does not reach equivalence and ultimately the 
market. These days are reduced or enhanced by the manufacturer's 
ability to interpret regulations, comply with those regulations, 
and establish substantial equivalence to a product which was on the 
market prior to 1976. 
THE PROBLEM 
Statement of Problem 
The Medical Device Amendments of 1976 (Public Law 94-295) 
consolidated and expanded existing federal authority over medical 
devices. It enacted a system of regulating safety and effectiveness 
Page 3 
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of medical devices in proportio~ to the degree of risk they posed. 
This meant that any medical device manufactured after the Medical 
Device .Amendment of 1976 needed to establish that it was 
substantially equivalent in terms of content, composition, intended 
use and related risk. If this equivalency was established, FDA 
required nothing more than pre-market notification. If found not 
to be equivalent; other more rigorous requirements were imposed 
(e.g., multi-centered clinical trials). Conducting multi-centered 
clinical trials was very expensive and resource intensive. Even if 
equivalence could be e&·c.dblished, delays, due to misinterpretation 
of guidelines, inability to provide =equired information, etc., in 
securing the FDA's disposition could also incur additional 
expenses. 
The task of i.mplementing some of the key provisions and 
managing the cost of some provisions relative to the incremental 
gains in safety and effectiveness have placed considerable burdens 
on the medical device industry. Regardless of efforts by FDA to 
streamline the approval process, Drew (1986) emphasized that many 
of the large firms and a majority of the small firms were at the 
leading edge of science and technology, but had relatively little 
knowledge and experience in meeting regulatory requirements. This 
situation might only slightly delay the marketing of a product or 
might result, in the most extreme case, in the demise of an 
organization. The purpose of this study was to assess the impact 
Page 4 
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of regulatory compliance on time to equivalence in the orthopaedic 
medical device industry. 
The data gathered regarding the dependent variable, time to 
equivalence (days) and product characteristics was obtained from 
a document referenced in the Introduction section of this paper, 
The Sl0Ck) Register. This annually published document provided the 
following information: product classification, product type, 
sponsor or manufacturer's name, submission date, and date of 
substantial equivalence. It also listed the number of requests by 
FDA for further information before disposition was reached, and 
elapsed days from time of sci:>mission to time of equivalence. 
The predic~or or independent variables, X, were: number of 
years manufacturing medical devices, organizational size, and 
regulatory department size, if present. 
One-way analysis of variance was performed to assess the 
difference in organizational characteristics and time to 
equivalence. The criterion or dependent variable was measured in 
tinie (days) to equivalence. 
The independent variables were discrete dichotomies and 
ordinal levels of measurement. Those variables included the 
following: the type of medical device manufa~tured, the presence 
or absence of an in-house regulatory department, regulatory 
training experience, number of medical devices manufactured, use 
of out-of-house regulatory consultants, attitude toward written 
Page 5 
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communication with FDA, attitude toward oral communication with 
FDA, attitude toward regulatory training, attitu.de toward the 
presence of an in-house regulatory department, attitude toward the 
use of out-of-house regulatory consultants, and production costs. 
As indicated above, Research Question Number 2 and Hypotheses 
2.1 listed below entailed evaluation of the type of medical device 
manufactured. This classification scheme developed by FDA was 
explicated in the Definitions section of this document. A device 
was classified as class I, II, or III based upon the degree of risk 
regarding safety and effectiveness of the device and its 
complexity. Orthopaedic dsvice classification I would include 
simple device types which pose minimal risk to the patient (e.g., 
bandage, cast, forceps, etc.). Classification III would include 
devices which present a significant risk, such as, shoulder 
prosthesis or arti!icial heart. 
Further analysis entailed the investigation of the combined 
influence of independent variables which best predicted time to 
equivalence. 
All analyses were stratified by the ~ears 1977 through 1987. 
If distribution imbalances we~e observed, nonparametric tools 
were imposed. 
Prognostic information was retrieved via mailed 
questionnaires, phone interviews, and personal interviews • 'l'he 
questionnaire enclosed in Appendix C served as the data collection 
Page 6 
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vehicle. 
~ll hypotheses were stated in the null. 
Ultimately, this study was designed to investigate the 
influences on the process of notifying FDA of an orthopaedic 
medical device manufacturer's intent to market a product which was 
substantially equivalent to a device manufactuzed prior to the 1976 
Medical Device Amendments. 
Research Questions 
Research Question Number 1 
What is the relationship between time devoted to establishing 
an FDA disposition of substantial equivalence for an orthopaedic 
medical device and related costs and resource consumption? 
Hypothesis 1.1. There is no relationship between time (days) 
needed to establish equivalence and the number of years a 
company has been manufacturing medical devices. This 
hypothesis relates to question numbe= 1 en ths questionnaire. 
Hypothesis 1.2. There is no relationship between time (days) 
needed to establish equivalence and the number of employees 
in an organization. This hypothesis relates to question number 
2 on the questionnaire 
Hypothesis 1.3. There is no relationship betweeu time (days) 
needed to establish equivalence and the number of employees 
in the regulatory department. This hypothesis relates to 
question number 2 on the questionnaire. 
Page 7 
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Research Question Number 2 
Is there any difference between xespondentd (companies) who 
possess or do not possess certain identified characteristics and 
time required to establish equivalence? 
Hypothesis 2.1. There is no difference between the type of 
medical device manufactured and time to equivalence. This 
hypothesis relates to information secured from The 510 Ck) 
Register. 
Hypothesis 2 . 2 • There is no di£ f erence between companies 
having in-house regulatory departments and companies that 
don't have in-house regulatory departments on time to 
equivalence. This hypoth~sis relates to question number 2 on 
the questionnaire. 
Hypothesis 2.3. There is no difference between companies who 
received regulatory compliance training and companies who 
didn't receive regulatory compliance training on time to 
equivalence. This hypothesis relat~s to question number 3 on 
the questionnaire. 
Hypothesis 2.4. There is no difference between companies who 
manufacture one medical device and companies that manufacture 
more than one device on time to equivalence. This hypothesis 
relates to question number 3 on the questionnaire. 
Page 8 
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Hypothesis 2. 5. There is no difference between companies who 
report using regulatory affairs consultants and companies that 
don't use regulatory affairs consultants on time to 
equivalence. ~his hypothesis relates to question number 2 on 
the questionnaire. 
Research Question Number 3 
Is there any difference between time to equivalence and 
respondent's (company's) attitudes about selected characteristics 
of the regulatory process as having an impact on time to 
equivalence? 
Hypothesis 3.1. There is no difference between the companies 
who perceive FDA written communication as having an impact on 
timely compliance and companies that don't perceive FDA 
written communication as having an impact on timely compliance 
on time to equivalence. This hypothesis relates to question 
number 5 on the questionnaire. 
Hypothesis 3.2. There is no difference between companies who 
perceive FDA oral communication as having an impact on timely 
compliance and companies that don't perceive FDA oral 
communicatiQP. as having an impact on timely compliance on time 
to equivalence. This hypothesis relates to question number 6 
on the questionnaire. 
Page 9 
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Hypothesis 3.3. There is no difference between companies who 
perceive the Office of Small Manufacturers Assistance (OSMA) 
regulator:1r compliance training as having an impact on timely 
compliance and companies who don't perceive the OSMA 
regulatory compliance training as having an impact on timely 
compliance on time to equivalence. This hypothesis relates to 
question number 7 on the questionnaire. 
Hypothesis 3.4. There is no difference between companies who 
perceive having an in-house regulatory department as having 
an impact on timely compliance and companies who don't 
perceive having an in-house regulatory department as having 
an impact on timely compliance on time to equivalence. This 
hypothesis relates to question number 8 on the questionnaire. 
Hypothesis 3.5. There is no difference between companies who 
perceive the use of outside regulatory affairs consultants as 
having an impact on timely compliance and companies that don't 
perceive the use of outside regulatory affairs consultants as 
having an impact on timely compliance on time to equivalence. 
This hypothesis relates to question number 9 on the 
questionnaire 
Page 10 
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Research Question Number 4 
What combination of independent variable mea~ures best 
predicts time to eq-uivalence? This research question takes 
information from all the questions on the questionnaire. 
Research Question Number 5 
What variables appear to have an impact on time to equivalence 
as perceived by the company respondent? This research question 
relates to questions number 4 and 10 on the qu~ationnaire. 
Importance and Relevance 
Numerous changes in FDA regulations over the past ten years 
have created a dynamic environment for firms in the medical device 
industry. Al though the overall picture for the medical device 
industry was optimistic and growing, the repercussions of the 1976 
legislation presented serious problems. Cost of compliance, FDA 
expectations, FDA dispositions, and device reclassifications all 
placed a strain on individual firm resources and management. Any 
effort to conserve resources and reduce costs while maintaining 
market position was viewed as cost effective and beneficial to 
management in medical device enterprises. 
Specifically, compliance with federal regulations and related 
strategic adaptation in relation to resource allocation and cost 
reduction in the medical device industry had not been directly 
Page 11 
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investigated in the past. Financial survival and industry 
leadership may directly be linked with regulatory compliance. Of 
importance might be the investigation of the relationship between 
regulatory dispositions and medical device corporate short/long 
term planning in response to regulatory agencies requirements. Does 
a pattern exist in which predictable elements emerge which, with 
some high probability, contribute to reduced days in securing FDA 
disposition (equivalence) regarding a product? 
It would be of value if a manager could anticipate with some 
reliability the approximate number of days it would take for that 
product tc reach equivalence once a Sl0(k) had been submitted to 
FDA. With this knowledge there could be some planning alterations 
in terms of marketing, sales, and production strategies. 
Assuming the federal social regulations inherent in the FDA 
guidelines were in accordance with the degree of risk associated 
with the device and that these guidelines did provide an adequate 
audit trail which, if followed, were cost accountable at the very 
least, the regulatory department manager or corresponding 
responsible individual could and should benefit from being well 
versed in the avenues essential to reaching equivalence. 
One of the major decisions related to the cost of the 
equivalence process was the use of in-house versus out-of-house 
regulatory professionals. 
Page 12 
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Management must be able to weigh certain variables to 
determine when it was cost effective to bring in outside 
consultants to assist in the interpretation of device related 
guidelines. There were multiple factors for the chief executive to 
take into account when considering whether to use in-house or 
outside regulatory professionals. When evaluating available 
resources and possible costs in establishing equivalence not only 
on one device at one point in time, but equivalence for numerous 
devices over years, a chief executive might consider the following 
possibilities: expanding the responsibilities of present employees, 
developing a new department (Regulatory Affairs), and/or hiring 
more employees for the new department. If a regulatory department 
was already in-house, the chief executive may need to hire more 
employees to meet the increased demands, or enlist the assistance 
of regulatory consultants outside of the firm. This study evaluated 
the above implied variables and associated patterns. 
Research Assumptions and Limitations 
To gain a greater understanding of the limitations of this 
research, it was necess~.i' extend the review to key 
methodological characteristics. In order to do so, three aspects 
of the research design were examined - 1) data source, 2) 
measurement of profitability, and 3) data analysis. 
Page 13 
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The different types of measurement procedures employed in 
operationalizing a construct played a critical role in determining 
the validity of the results. These procedures (e.g., content 
analysis, quantitative calculation, investigator inference) 
translated data sources (e.g., questionnaire, publicly available 
510lk) Register) into specific types of measures (e.g., 
retrospective nominal and ordinal scales, trend lines). 
Data analysis referred to whether the type of anclysis 
employed was qualitative or quantitative. This characteristic was 
important for differentiating findings which were primarily useful 
for theory building from those which were useful to theory testing. 
Methodological Tradeoffs 
Miller and Friesen (1982) in reviewing the characteristics of 
different approaches to longitudinal analysis of orga~izations, 
identified three major dimensions along which research t~adeoffs 
were generally made: 1) breadth of focus, i.e., number of 
variables, 2) sample size and 3) the extent to which quantification 
occurs. Relative ease in analy~is and interpretation were generally 
achieved at the exp~nse of specification error created by an overly 
narrow scope, lack of generali~ability created by overly small 
sample size, or lack of reliability due to a non-quantitative 
analysis approach. 
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These shortcomings in turn lead to a body of non-cumulative 
findings. On the other hand, cumulative findings were often 
achieved at the expense of a lack of appropriate data and 
inadequate model construction due to quest for overly broad scope. 
Data collection tended to be inefficient and over-generalization 
tended to occur because of an overly large sample size and over-
dependence on quantitative analysis that ignored the importance of 
intuition-guiding 'soft data'. 
In addition, the existence of nonlinea~ities and intrasample 
differences tended to be overlooked. All of these problems lead to 
findings that were cumulative, but difficult to interpret. 
The above highlighted precautions and concerns bring about the 
following research assumptions and delimitations: 
Assumptions 
1. Federal social regulation did impact time to equivalence 
and related financial profits in orthopaedic medical device firms 
to a varying degree. 
2. The impact of federal social regulation upon time to 
equivalence could be perceived by top management (Regulatory 
Affairs Department Director) of medical device firms. 
3. The sampled population was fairly homogeneous when 
stratified by calendar year. 
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4. Profit-making was essential to the 
business in the United States. 
5. Respondents to the questionnaire 
individuals as to impacts of regulations and 
characteristics. 
purpose of any 
were informed 
organizational 
6. The research design was adequate for the purpose of the 
7. The analysis of data did not significantly alter 
relationships among variables and gave an adequate representation 
of relationships. 
8. The data collected were a satisfactory indication of the 
impact of federal social regulation upon time to equivalence for 
orthopaedic medical device manufacturers. 
Delimitations 
1. The questionnaire was distributed to top-level executives 
of randomized orthopaedic medical device firms throughout the 
United States. 
2. The research was limited to information willingly 
supplied by participant firms. 
3. The measurement of time to equivalence and related 
profitability in the orthopaedic medical device field as it relates 
to federal regulation was a relatively new endeavor. Conclusions 
based upon findings of the study should not be considered 
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appropriate for generalization to areas other than those 
encompassed by the present study. 
4. The role of the researcher was to evaluate the influences 
of a regulatory process, as well as, determine the dynamics of 
emergence in the orthopaedic medical dev~ce industry. These two 
motives for exploration could have introduced some conflicts and 
bias. 
Definitions 
Corporate Social Responsibility: This term referred to compliance 
measures implemented by a corporation which could alter or adjust 
product design, development; manufacturing, procurement, or 
distribution in response to health and safety requirements 
stipulated through federal social regulation. 
Pre-amendment Devices: Devices on the market before May 28, 1976, 
when the Medical Device Amendments were enacted. 
Post-amendment Devices: Devices put on the market after May 28, 
1976. Unless shown to be substantially equivalent to a device that 
was on the market before the amendments took effect, these devices 
are automatically placed in Class III. A manufacturer may petition 
FDA for reclassification. 
Substantial Equivalence: Although not defined by law, congressional 
intent was to ensure fair treatment of post-amendment devices that 
were similar to :pre-amendment devices, as well as limit the number 
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of new devices that would require premarketing approval. 
SlOlk) Process: These notifications were the formal notices 
submitted to FDA by the medical device industry in order to quickly 
obtain FDA permission to market medical devices. 
Time to Equivalence: This defined the time measured in days 
required by FDA to come a disposition that a device is 
substantially equivalent to an already approved device or to a 
device marketed prior to May 28, 1976. 
Class I Medical Device: Class I, general controls, encompasses 
devices for which general controls were sufficient to provide 
reasonable assurances of safety and effectiveness, i.~:. tong-ue 
depressor. 
Class II Medical Device: Class II, performance standards, contained 
devices for which controls were considered insufficient to ensure 
safety and effectiveness and information existed to establish 
performance standards, i.e. X-ray devices. 
Class III Medical Device: Class III, premarket approval, applied 
to devices for which general controls were insufficient to ensure 
safety and efficacy. Information did not exist to estcmlish 
performance standards and the device supports life, prevents heal th 
impairment, or presents a potentially unreasonable risk of illness 
or injury, i.e. implantable heart valve. 
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Office of Small Manufacturers Assistance COSMA) - This office was 
included in the 1976 enactment of the Medical Device Amendments to 
the Food, Drug, and Cosmetic Act. This legislation provided for the 
establishment of an identifiable office to help small manufacturers 
of medical devices understand and comply with the new FDA 
requirements for these products under that law. 
Swmnary 
Regulation of orthopaedic medical device manufacturers was of 
two basic types: ( 1) economic regulation aimed at maximizing 
profits and (2) social regulation aimed at accomplishing social 
objectives. Both types affected companies who manufacture medical 
devices to a varying degree. 
Research was conducted to determine relationships and 
differences between federal social regulation, company 
characteristics, and time to equivalence. Research questions 
examining the impact of federal social regulation upon time to 
equivalence for orthopaedic medical device manufacturing firms were 
stated. 
Delineation of questions separated dependent variables, 
independent variables, and their elements • General linear model and 
analysis of variance approaches were used as the research method. 
Criteria for data sources were outlined and definitions of specific 
terms as used in the study were discussed in this chapter. 
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CHAPTER II 
REVIEW OF LITERATURE 
This section presented a review of the literature covering 
aspects of social regulation and the medical device industry. An 
historical dimension was presented on the interrelationship between 
government policy and the operation of business firms. This section 
concluded with an overview of government regulation of medical 
devices by the Food and Drug Administration. 
Historical Dimension 
Social Regulation 
Social regulations have undergone the greatest growth in terms 
of agencies and expenditure of government funds. weidenbaum (1977) 
identified major expansion in six areas: job safety, traffic 
safety, consumer product, personnel practice and discrimination in 
employment, consumer finance, environment and resources. The growth 
of social regulation has continued extensively. From the period of 
1970 to 1977, the number of social regulatory agencies increased 
from 12 to 17, and expenditures for these agencies rose from 
$1,449.3 million to $7,318.3 million (Miller and Yandle, 1979). 
In the area of job safety, federal and state governments have 
passed laws affecting nonunion workers. Included is unemployment 
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compensation, minimum wage laws, social security ~~ws, and safety 
laws. The Occupational Safety and Health Act (OSHA) of 1970 gave 
the federal government a tremendous amount of power and authority 
to set and enforce safety regulations even in the smallest of firms 
(Nicholson, Litschert, and Anthony, 1974). 
In the area of traffic safety, the NHTSA has actively 
regulaterl eafety standards affecting the design of automobiles. For 
example, regulated safety standards include "uniform bumper 
heights, damage limitations resulting from 5 mph test crashes, and 
mandatory seat belts, air bags, or other restraint :mechanisms" 
(Ferreira, 1982). 
In the area of consumer products, fedezal regulatory interest 
in product safety-related matters has grown enormously. Several new 
agencies with interests in product safety have been established, 
including the Consumer Product Safety Connnission (CPSC) in 1972. 
The Consumer Product Safety Act required the maintenance of records 
to ensure that firms are complying with its provisions and granted 
the CPSC access to these records (Eads, 1981). 
A number of preexisting agencies with product safety 
responsibilities were strengthened. Among those are the Federal 
Trade Connnission (FTC), the Food and Drug Administration (FDA), and 
the Department of Agriculture (USDA). 
In the area of personnel practice, the Equal Employment 
Opportunity Connnission (EEOC) and OSHA have impacted business 
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considerably. An idea proposed by Smith (1981) that would 
substitute for OSHA regulations would be a $500 deductible for 
every successful worker's compensation claim.!' with that deductible 
·then paid by the employer. This idea did not include health 
co.-'=!rage. 
In +lie area er consumer finance, federal credit programs 
assumed three forms: direct lending by United State's government-
owned agencies, direct lending by privately owned agencies 
sponsor.ad by the federal government to serve public interest, and 
the insuring or guaranteeing of loans extended directly by private 
lenders to private borrowers (Swanson, 1974). The immediate 
function of federal credit agencies was to provide credit 
accommodation for borrowers generally considered marginal or at 
least subject to relatively high risk arising from cyclical 
fluctuations or other special factors. In a more fundamental sense, 
as Swanson ( 1974) put it, these agencies were oriented toward 
redistributing economic resources for achieving greater economic 
stability in certain sectors of the economy. 
In the area of environmental programs, the Environmental 
Protection ~gency (EPA) contributed greatly. The EPA set emissions 
standards for power plants based upon the location of each plant, 
current ambient concentrations of air pollutants, a computer model 
for the plant's impact upon local air quality, and a consideration 
of the technology available for controlling the pollutants (Bardach 
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and Kagan, 1982). Other regulatory programs, such as the Clean Air 
Act of 1970, distinguished between old and new facilities and 
placed less stringent controls upon existing plants. Under the Act 
and its amendment of 1977, all cars sold in the United States must 
eventually achieve a 9 0 percent reduction in carbon monoxide, 
hydrocarbons, and nitrous oxide emissions from the level of 1970 
controls (Bardach and Kagan, 1982). 
Social Regulation and the Medical Device Industry 
Medical device regulation was first adhered in the Federal 
Food, Drug, and Cosmetics Act of 1938. Although this act is best 
known for requiring pre-market notification for the safety of new 
drugs, devices also came under its expansive umbrella. The 1938 Act 
defined medical devices in the Federal Register as: 
•••• instruments, apparatus, and contrivances, including 
their components, parts and accessories, intended ( 1) for 
use in the diagnosis, care, mitigation, treatment, or 
prevention of disease in man or other animals; or (2) to 
affect the structure or any function of the body of man 
or other animals. 
'!'he 1938 act authorized FDA to inspect any site in which 
devices were manufactured, processed packed, or held. It also 
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authorized FDA to seize adulterated or misbranded medical devices. 
FDA also had the power to request an injunction against their 
productioni distribution, or use; or seek criminal prosecution of 
the responsible manufacturer or distributor. But the agency could 
not take action until after a device had been marketed. 
In the early regulatory actions taken against adulterated or 
misbranded devices, FDA was able to use expert testimony to prove 
its allegations. Over time, however, FDA increasingly had to test 
devices suspected of violating the law in order to remove these 
devices from the market (U.S. Congress House Report No. 94-853). 
As medical devices became more complex.after World War II, 
attention turned to the regulation of legitimate devices as well. 
But FDA could still act only after devices were distributed and 
also had the burden of proving that a particular item was 
misbranded or unsafe, because devices were not subject to premarket 
approval (AMP, Inc. v. Gardner, 1968). 
In the late 19608 , however, the courts ruled that certain 
products ( such as nylon sutures and antibiotic-sensitive discs) 
that fell in the grey area between drugs and devices could legally 
be considered drugs and subject to premarket approval requirements 
for new drugs (12,302). Subsequently, FDA regulated as "new drugs" 
such products as some intrauterine devices (IUDs), some contact 
lenses, and some in vitro diagnostic products. 
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Furthermore, during the late 19 6 0 's, Congress addressed public 
health problems associated with radiation emissions from electronic 
products. Under the Radiation Control for Health and Safety Act of 
1968 (Public Law 90-602), Congress established a radiation control 
program to authorize the establishment of standards for electronic 
products, including medical and dental radiology equipment. 
From the early 1960's to 1975, six Presidential messages were 
given and 2 8 bills were introduced to enact medical device 
legislation. 
A 1969 Depa....--...:ment of Health, Education, and Welfare review of 
the scientific literature for injuries associated with medical 
devices that was conducted by the Cooper Committee (named after its 
chairman, Theodore Cooper, then Director of the National Heart, 
Lung, and Blood Institute of the National Institutes of Health) 
estimated that over a 10-year period, 10,000 injuries were 
associated with medical devices, of which 731 resulted in death 
(U.S. Congress House Committee Hearing No. 93-61). 
The vast majority of these problems were associated with three 
device types: artificial heart valves, 512 deaths and 300 injuries; 
cardiac pacemakers, 89 deaths and 186 injuries; and intrauterine 
contraceptive devices, 10 deaths and 8,000 injuries (U.S. Congress 
House Committee Hearing No. 93-61). As observers noted, however, 
there had been no sensational event or public tragedy to spur more 
stringent regulation of medical devices such as the events leading 
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to the 1962 Drug Amendment (Igelhart, 1973). 
Additional examples of hazards associated with medical devices 
were documen.ted in congressional hearings in 1973. These included 
prosthetic and orthopaedic implants of improper materials, cardiac 
defibrillators with faulty electrical circuitry, incubators in 
which temperatures reached as high as 145° F, plastic tracheotomy 
tubes with obstructions, and faulty valves on emergency oxygen 
respirators (U.S. Congress House Committee Hearing No. 93-61). 
The developments just described eventually culminated in the 
enactment of the Medical Device Amendm~nts of lS76 (Public Law 94-
295). 
Today, while public well-being and fraudulent "miracle cures" 
continue to demand FDA's attention, it is the number and diversity 
of legitimate medical devices that present the greatest problems 
in regulation. There are more than 1,700 types of medical de~ices; 
the various models and sizes of each type add up to between 40,000 
and 50,000 separate products (Drew, 1986). These types of de,.rices 
range from the simplest (such as tongue depressors) to the most 
complex (such as magnetic resonance imagers), and from the most 
routine (such as urine collection bottles) to the most critical 
and life-preserving (such as artificial hearts). 
These medical devices were produced by approximately 8,000 
firms, many of them small, relatively new enterprises (Drew, 1986). 
Over 95 percent had fewer than 500 employees, and half of those had 
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fewer than 50 employees. 
Many of these small firms were at the leading edge of science 
and technology, but had relatively little knowledge and experience 
in meeting regulatory requirements. Because those requirements 
depended on the nature of the device, rather than the size of the 
company producing it, small firms had to spend a large proportion 
of their resources for regulatory compliance than larger firms. 
Recognizing this situation, FDA established th~ Division of 
Small Manufacturers Assistance (DSMA) to help small firms to cope 
with the regulations. 
All medical devices were subject to some level of regulation 
by FDA, but the nature and the degree of that regulation varies. 
The more hazardous the device, the greater the regulation. The 
intent was to protect users and patients, while imposing the least 
possible regulatory burden on producers of devices. 
This ~=s accomplished by classifying medical devices into 
three groups --- Class I, Class II! Class III --- with the least 
hazardous devices in Class I and the most hazardous in Class III. 
The classification of a device determined which regulatory 
•channel" it follows. 
Class I devices, such as adhesive bandages, toothbrushes and 
tongue depressors, present risks that can be managed"by "general 
controls•. These gen~ral controls represented a regulatory 
baseline, which all manufacturers, importers, and distributors must 
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meet. They included registration of the firm with FDA and periodic 
listing of all medical devices produced or handled by the firm. 
Also, whenever a firm intended to introduce a new or significantly 
modified device to its product line, it had to notify FDA at least 
90 days before marketing the device. 
Other general controls included adequate labeling and good 
manufacturing practices in producing devices. Drew (1986) reported 
460 types of Class I medical devices, 27 percent of the total 
number of medical device types. 
Class II devices, such as cardiac monitors, anesthesia 
machines and defibrillators, were subject to performance standards 
in addition to general controls. A performance standard was a set 
of specifications that the device must meet to be safe and 
effective. 
The process of developing a performance standard was long and 
difficult; and no standards had been put in place by then. 
Approximately 1,100 types of devices, or 65 percent of the total, 
were included in Class II (Drew, 1986). 
Class III devices were those with the greatest risk of injury, 
or that supported or $Ustained life and had an unknown degree of 
risk. They included artificial heart valves, heart-lung machines, 
and lithotriptor. 
Class III devices were subject to general controls and pre-
market approval. This meant r.hat firms must obtain FDA approval 
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before marketing the device. ~~y devices that w~re uot marketed 
before the Medical Device Amendments were automatically Class III 
devices (unless FDA found that they were substantially equivalent 
to a Class I or Class II device). Approximately 140 devices were 
Class III, or 8 percent of the total (Drew, 1986). 
Pre-market approval depended on the firm showing that the 
device is safe and effective, usually based on clinical studies or 
other clinical experience with the device. In order to develop 
clinical data for such approval, an investigational device 
exemption (IDE) had to be obtained from FDA. An IDE permitted 
limited distribution under specific conditions for the purpose of 
studying the device. The IDE provided for the clinical use of 
devices at a specific number of locations, based upon laboratory 
and animal tests which predicted that clinical use in humans would 
be potentially helpful to patients. 
A number of regulatory requirements applied to medical device 
firms after marketing begins. The general controls ( including 
regi~tration, listing, and good manufacturing practices) continued 
to apply. The Food, Drug, and Cosmetics Act required that FDA 
inspect all medical device manufacturers that produce Class II or 
Class III devices at least once every two years. Companies who made 
only Class I devices were inspected at least once every four years. 
FDA could inspect a firm more frequently if problems occurred with 
its products. 
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Amore recent addition to the post-marketing requirements was 
the medical device reporting regulation, which went into effect in 
1984. Under this regulation, medical device firms were required to 
report to FDA any death or serious injury that may be related to 
one of their products, as well as any malfunction that could have 
caused death or se:ious injury. 
The Medical Device Amendments protected consumers in an area 
where the complexity of the technology prohibited them from 
personally assessing the safety and efficacy of the products used 
to prevent, diagnose or treat their illnesses. Although there was 
basic agreement within the medical device industry that FDA's 
charge of imposing social regulation was necessary, many 
manufacturers question the benefits versus the regulatory 
expenditures involved in compliance. 
Regulated Industry Research 
In 1985, Ungson, J'ames & Spicer evaluated the effects of 
regulatory agencies on organizations in the wood products and high 
technclcgwf/electLonics industries. There were three distinct but 
related phases to their research. First, they conducted preliminary 
interviews with trade associations, regulatory agencies, and 
selected firms in the wood products and high technology/electronics 
industries to improve their understanding of business-government 
relationships. Second, they developed a survey questionnaire, and 
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administered it to 80 firms in the two industries. They also 
obtained regulatory compliance costs of some firms and used these 
to corroborate questionnaire responses. Third, they conducted post 
hoc interviews with managers of 14 firms to clarify questionnaire 
findings and to elicit participants' reactions to the results. 
Four specific hypotheses were stated and tested. Hypothesis 
1 contended that sectors of the task environment varied in terms 
of importance, predictability, and controllability to 
organizations. They found that government regulatory agencies were 
significantly different from all other sectors in terms of 
predictability and controllability. 
The second hypothesis contended that organizational 
adjustments to different sectors of the task environment varied. 
They found, for the most, part that adjustments made in both 
industries in response to regulatory agencies consisted in hiring 
and firing personnel and minor changes in work standards and 
procedures. 
The third h~,t:IOthesis contended that regulatory agencies 
differed in terms of how their positions were perceived by 
organizations, and that these differences hold among industries. 
They found the frequency of inspections and di£ f icul ty in obtaining 
regulatory inforlliation had consequences upon m~~ale and were the 
most severe adverse characteristics of regulatory agencies. 
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The fourth hypothesis contended that assessments of agency 
issues varied with the size and age of the £inn. They found that 
larger, older f inns granted greater importance to regulatory 
agencies in their planning activities. Younger, smaller £inns 
perceived more hannful effects on morale arising from their 
interactions with regulatory agencies than did older and larger 
firms. 
Within the medical device industry McKay (1986) attempted to 
in~estigate the effects of the 1976 federal regulation amendment 
within the diagnostic imaging industry. He questioned how the 
medical device regulation effected net entry (e.g., the difference 
between the number of finns entering and exiting and industry) and 
concentration (e.g., the distribution of sales among finns in the 
industry). 
Regressions coefficients were produced for both net entry and 
concentration spanning years 1970 to 1980. He found that medical 
device regulation did not appear to significantly effect net entry 
or concentration in the diagnostic imaging equipment industry. 
Research Studies 
Parket & Eilbirt (1975) attempted to measure the absolute net 
income, profit margin return on equity, and earnings per share. 
Ninety-six firms responded to a survey. The profitability of 80 of 
these finns were compared to Fortune 500 firms. On all four 
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measures, the 80 firms proved to be more profitable. Some of the 
limitations of the study included no adjustment for risk. There was 
a questionable sample; performance was measured over a short period 
of time ( 12 months) ; performance criteria were inadequate; no tests 
for significance were performed. 
Heinz (1976) stipulated several measures such as return on 
assets, return on equity, and profit margins. He correlated 
Corporate Social Responsibility (CSR) ratings of 29 firms from a 
Business and Society Review survey with ret·~rn on equity. A 
significantly positive correlation between corporate social 
responsibility and return on equity was found. However, the small 
sample size and reliance on a reputational rating system were 
limitations. 
Sturdivant & Ginter (1977) established performance criteria 
of earnings per share over a ten year period. A population of 67 
high Corporate Social Responsibility (CSR) firms as identified by 
Moskowitz in the Business and Society Review were used in a survey. 
Twenty-three firms returned 130 questionnaires. The 67 firm 
population was also reduced to 28 firms and reclassified into four 
industrial groupings. Their research implied that high CSR firms 
{Best and Honorable Mention) outperformed low CSR firms. This study 
did not provide an adjustment for risk. They employed a t-test with 
a very small sample and the industrial categories were 
inconsistent. They also failed to identify a c11-."'"Vilinear 
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relationship revealed in the data between corporate 
responsibility and earnings per share. 
Alexander and Buchholz (1978) measured stock price increases 
over two years and five years. They used reputation ratings derived 
from Business and Society Review surveys. Corporate Social 
Responsibility (CSR) ratings were correlated with stock price 
increases over time and adjusted for risk. They determined that CSR 
had no effect on stock market performance. This study seemed to be-
limited by reliance on a questicnable sample and the performance 
measures were inadequate. 
Summary 
The role of government had been primarily to support business 
systems in their role of economic leadership and to mediate between 
business and society. Government's role had changed from judging 
how well business performed its social responsibilities -co defining 
what these responsibilities should be. The role of government was 
enlarged to include a regulatory function. A wave of legislative 
regulation of business followed. The rapid expansion of government 
controls had been associated with a growing dissatisfaction with 
the effects of regulations. 
Two widely accepted divisions of government regulation were 
economic and social. The basic reform strategy, according to 
Bardach and Kagan ( 1982), had animated the growth of federal 
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protective regulatory programs and had created a series of 
regulatory agencies, all for the purpose of the betterment and 
improvement, both socially and economically, of the operation of 
business and industry. 
The medical de7ice industry had been subject to both social 
and economic regulation. Food and Drug Administration (FDA) was the 
designated regulating agency responsible for creating and issuing 
guidelines for the medical device industry. Several regulatory 
developments in the medical device industry culminated in the 
enactment of the Medical Device .Amendmente of 1976. The economic 
and social consequences of these amendments have beer- evaluated 
since their enactment. 
The research studies which had been reviewed were related to 
social regulation and profitability in several regulated 
industries. One study surveyed managers in the wood and high 
technology/electronics industry as to the social and economic 
consequences of federal social regulation. A second study looked 
at net entry and concentration in the diagnostic imaging equipment 
industry. 
Further research studies were reviewed that employed survey 
questionnaires in evaluating organizational performance with 
respect to corporate social responsibility. 
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The study examined aspects of the impact of fedAr~, Qnc;~1 
regulation upon the time required to get a medical device through 
the FDA review process and onto the market for small and large 
firms in the orthopaedic medical device industry. The 
accomplishment of the study necessitated the collection of 
quantitative and opinion data from a geographically dispersed 
population of regulatory affairs managers. Data described the 
relationships and differences between elements of independent 
variables, company characteristics, managers' opinions, and the 
dependent variable, time to equivalence or FDA disposition. 
The methods of research adopted were descriptive and 
comparative in nature. Accordingly, the design involved descriptive 
and comparative quantitative and qualitative data collected via a 
survey method. 
The research questions were as follows: 
1. What is the relationship between time devoted to 
establishing an FDA disposition of substantial eauivalence for an 
orthopaedic medical device and related costs and resource 
consumption? 
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2. Is there any difference between respondents (companies) 
who possess or do not possess certain identified characteristics 
and time required to establish equivalence? 
3. Is there a any difference between time to equivalence and 
respondent's (company's) attitudes about selected characteristics 
of the regulatory process as having an impact on tir~e to 
equivalence? 
4. What combination of independent variable measures best 
predicts time to equivalence? This research question takes 
information from all the questions on the questionnaire. 
5. What variables appear to have an impact on time to 
equivalence as perceived by the company respondent? This research 
question relates to questions number 4 and 10 on the questicnnaire. 
Choice of Method 
In the classical formulations of how best to apply social 
research to organizational behavior, one of the recommended 
earliest steps was to develop intelligence about the problem in 
question. This process included forming adequate conceptual and 
empirical definitions, and assembling or gathering sufficient 
empirical data to provide a description of the problem in terms of 
its size, organizational location, and spatial distribution of the 
problem in question. 
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The precess described above has been attempted, to varying 
degrees of success, through the use of surveys investigating 
profitability and organizational behavior. Parket and Eilbert 
(1975) explored the profitability of 80 firms compared to Fortune 
500. Their performance criteria were absolute net income and profit 
margin~ Heinz (1976} correlated Corporate Social Responsibility 
with several measures such as return on equity and profit margins. 
He employed Business and Society Review survey ratings to compare 
29 firms on profitability. 
Sturdivant and Ginter (1977} had 23 firms return 130 
questionnaires querying executives regarding profit growth over 10 
year period. In addition, a classification procedure was employed 
to recategorize 67 sampled firms into four industrial groupings. 
Alexander and Buchholz (1978) used reputation ratings derived from 
Business and Society Review surveys. Social responsibility ratings 
were correlated with stock price increases over time and adjusted 
for risk. Aupperle, Carroll, & Hatfield (1985) used a forced-
choice survey instrument containing 20 items assessing strategic 
management and profitability. Eight hundred and eighteen chief 
executives listed in Forbes 1981 Annual Directory were sampled. 
Ginsberg's dissertation work ( 1986) at the University of 
Pittsburgh measured environmental attributes, organizational size, 
and performance through the use of a questionnaire. Questions were 
designed to investigate the changing competitive environment of 
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financial de:f>C ·dtory institutions since the enactment of the 
Depository Institutions Deregulation and Monetary Control Act in 
1980. 
Resnick's dissertation (1986) focused on the airline industry 
just after government deregulation in 1978. He attempted to 
determine what corporate policies and practices resulted from 
externally imposed events requiring critical judgment and how those 
policies and practices affected employee education and training 
programs as reported by corporate training directors. The study 
selected the largest U.S. airlines, as identified by employee size 
in 1984 and listed in the 1984 U.S. Airline Handbook. 
As evidenced by the use of guesti,_,,., ..... .;.,.~d cited above, a 
survey design which utilizes a questionnaire completed by top level 
executives is a viable and well recognized procedure for obtaining 
standardized information about organizational behavior and 
characterist:ics. 
The survey design that was implemented in this study 
represented an attempt to achieve a satisfactory tradeoff between 
the goals of generalizability, contextual realism, and precision. 
Survey designs have three basic characteristics: (1) systematic 
measurements were made over a series of cases yielding a rectangle 
of data; (2) the variables in the matrix were analyzed to see if 
they show any patterns; and ( 3) the subject matter was social 
(Marsh, 1982). 
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Babbie (1973) identified three basic types of survey designs: 
(1) cross-sectional surveys; (2) longitudinal surveys; and (3) 
c~o~s-sectional surveys that approximate longitudinal ones. 
In a cross-sectional survey, data were collected at one point 
in time from a sample selected to describe some larger population 
at that time. In a longitudinal survey, data were collected at 
different points in time and the research was able to report 
changes in descriptions and explanations. 
Major examples of longitudinal designs were trend, cohort or 
panel studies. Trend studies collected data from the same general 
population at different times. Cohort studies collected data from 
the same specific population at di£ ferent times. Panel studies 
collected data from the same specific sample at different times. 
In an "approximately longitudinal" survey, the data were 
collected at one point in time. Questions were presented which 
involved some notion of actual and perceived changes at different 
points in time. Examples of these questions were changes in 
employee size at progressive one year intervals from 1976 to 
present and perceived influence of regulatory documents produced 
by the federal government which stipulated guidelines at 
progressive one year intervals. 
Some schol;;.rs might argue that research on organizational 
change can only be considered genuinely longitudinal when data are 
collected at different periods of time. Miller & Friesen (1982) 
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defined longitudinal research as "those techniques, methodologies 
and activities which permitted the observation, description, and/or 
classification of organizational phenomena in such a way that 
process (i.e. , any sequence of changes in organizational variables) 
can be identified and empirically documented". 
Given the difficulties involved with collecting panel data 
(e.g. expensive, require a long time to collect, and face problem 
of sample attrition), a broader definition of "approximately 
longitudinal" was employed in order to support the utilization of 
uapproximately longitudinal" designs that used retrospective data 
collection in investigating profitability and regulations. 
Gregson (1975) and others found that descri~tions of 
historical events become increasingly unreliable over time. This 
was due to loss of memory and the recency effect (i.e., the 
tendency to rationalize and distort accounts of past behavior in 
terms of subsequent and more recent events and conditions). 
Nevertheless, there were also studies which showed that there 
was no significant difference in accuracy between recalling 
behavior which occurred 10 or more years ago and behavior which 
occurred two or three months ago (Gutek, 1978). It had also been 
shown that retrospective recall of past earnings was not 
substantially less accurats t:han tha.t obtained for current salary 
(Ferber & Birnbaum, 1979). 
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Moreover, Powers, Goudy, & Keith (1978) conduct~d a study 
which indicated that while recall techniques may have little 
utility for descriptive purposes, they may be used cautiously in 
correlational studies. Finally, there was evidence which showed 
that survey methods employing collection of retrospective or recall 
data were reliable provided certain precautions (such as not asking 
respondents to describe events that have a strong emotional 
component regarding themselves) were taken (Moss & Goldstein, 1979; 
Power & Huber, 1982). 
Research Population 
Although medical equipment companies in this country have had 
a fairly stable and rapidly growing economic and technological 
environment, orthopaed.lc medical device manufacturers have been 
directly touched by regulatory change due to the risk they pose. 
Other reasons for focusing on companies that manufacture 
orthopaedic medical devices include the following: (1) they 
represent a relatively homogeneous group; {2) they represent 
approximately 10-15% of the 40,000 - 50,000 medical devices that 
cover the 1700 types sold in the U.S. and will be used at least 
once by each man, woman and child in this country and many others; 
(3) accessibi!.ity to regulatory affairs managers is relatively 
high. 
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Data sources were small and large orthopaedic medical device 
manufacturing firms throughout the United States. Selection of 
firms began with a review of The 510(k) Register in which was 
listed all companies that have filed SlO(k) premarket notifications 
since the enactment of the 1976 medical device amendment. The 
SlO(k) Register provided a product index which distinguished 19 
diffsrent medical device classifications of which orthopaedic was 
one. Within each classification was a product coding system. Firms 
we~e chosen from product coding categories which had no less than 
ten firms represente~. There were two reasons fox this selection 
process: ( 1) these categories represented companies that were 
diverse in terms of size and number of products manufactured, and 
(2) these companies functioned in the most competitive markets. 
Instrumentation 
A researcher-designed survey questionnaire was constructed to 
enable specific categorization of data. The most appropriate 
technique of observation for collection of data from firms' 
management was through use of a questionnaire. But a review of the 
literature showed no standardized instrument had been developed to 
measure the research dimensions of the relationships and 
comparisons among the particular variables of the present research. 
The final instrument consisted of a letter of transmittal 
(Appendix B) and a questionnaire (Appendix C) with instructions. 
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The questionnaire was designed to capture quantitative data 
and to quantify opinion duta. =he questionnaire consisted of three 
pages. The first two pages contained tables which provided the 
subject with a quantitative framework through which relationships 
and comparisons could be made from 1977 through 1987. The third 
page contained a table which provided the subject with a 
qualitative framework through which comparisons among elements of 
variables could be indicated quantitatively. 
The design of the questionnaire was guided by two primary 
objectives: 1) assure the capture of complete data, and 2) 
facilitate the ease and speed of completion. As a result, the first 
two pages of the survey consisted of binary responses or short, 
numeric fill-ins. This constituted a combined closed and open form 
question design. 
Since the principal objective of this study was to evaluate 
the influences on timely compliance over time ( 1977 - 1987), 
questions one through four were ordered chronologically. This 
allowed for historical comparisons and associations with events in 
industry and government. In addition, initial, pre-study interviews 
with regulatory affairs managers in which open-ended questions were 
asked indicated that continuity and clarity would be preserved if 
the questionnaire was designed as presented in Appendix C. 
Questions five through ten were also designed to evaluate the 
influences on timely compliance. Questions five through nine were 
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constructed as Likert attitude scales. Favorable or unfavorable 
attitudes on five Likert-type categories were requested. Although 
the respondents were familiar with the subject matter, a "no 
opinion" category was supplied as one alternative to assure that 
each question was completed. Question ten was included as an open-
ended query designed to yield information which may not have been 
addressed on the questionnaire. Although the pilot study which was 
incorporated into this research had as one objective the 
prioritization of questions, it was felt that the respondents 
needed one other vehicle to express their perceived influences on 
timely compliance. 
The letter of transmittal was designed as suggested by Borg 
and Gall (1979). Those intentions which guided the design of the 
transmittal letter were as follows: 1) give the respondent a good 
reason for completing the questionnaire, 2) explain the purpose of 
the study, 3) reference the respondent's professional status, 4) 
emphasize the importance and significance of the study, 5) assure 
the respondent's anonymity, and 6) offer to send the respondent a 
copy of the results. 
In addition, the transmittal letter was refined through the 
pilot study. The participants were asked to evaluate the 
transmittal letter with regard to composition, raalism, accuracy, 
and relevancy. Appendix A includes the pilot study cover letter. 
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Pilot Study 
A pilot study was incorporated due to the lack of research 
documented in the literature which provided information relevant 
to this research. Min~l information was available about the 
medical device industry, regulatory professionals, the regulation 
of medical devices, and the interaction of all three. 
In an effort to standardize and validate the content, format, 
and delivery of the research questionnaire, a sample of 14 
representative medical device manufacturers were asked to 
participate in the pilot study. This selection process, although 
not subjected to any form of randomization, was purposive, The 
pilot study par~icipants were chosen based upon their knowledge of 
the industry, their willingness to participate, and their interest 
in the research project. 
Six participants or questionnaire evaluators were queried via 
the mail. A cover letter soliciting their assistance in the pilot 
study (Appendix A), the transmittal letter (Appendix B), and the 
questio!Ulaire (Appendix C) were forwarded. Their comments were 
requested regarding both the transmittal letter and questionnaire. 
Eight participants or reviewers were interviewed by this 
researcher at the 1989 Annual Regulatory Professional Society 
meeting in Washington, D. C. Comments were sought regarding the 
content and validity of the questionnaire. Specifically, these 
reviewers were asked to consider each questionnaire item's 
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relevance to the purpose of the study, that is, timely compliance. 
The logic and soundness of each item was assessed. Then the 
questionnaire was reassessed as a composite entity. This form of 
evaluation primarily consisted of face validity comparisons rather 
than content validity. In addition, since no criterion measures 
were available with which to correlate the questionnaire items, 
predictive and concurrent validity checks were not possible. 
Do to the nature of the test or questionnaire, it was 
difficult to calculate a coefficient of internal consistency or 
equivalence. As a result, the unavailability of an alternative form 
of the questionnaire mandated the calculation of a coefficient of 
stability only. Furthermore, this test-retest reliability 
measurement was limited to four respondents. The delay in 
admiuistration was one day, approxil4ately 24 hours. The reliability 
coefficient was computed to be 89%. 
However, this meeting in Washington permitted pre-study 
establishment of baseline variable values. All of these respondents 
were regulatory affairs professionals actively employed within the 
medical device industry. 
All suggestions and comments were collected. Suggestions were 
incorporated if consensus (more than one reviewer had a similar 
concern) was reached regarding a variable. One consequence of this 
review process was the elimination of two questions which focused 
on the direct impact of compliance upon time to equivalence as it 
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relates to increased or decreased production costs. Most reviewers 
felt unqualified to supply specific information regarding 
production costs since this was not their area of expertise. 
Overall, the reviewers found the transmittal letter and 
questionnaire did address the research questions being evaluated 
in this research endeavor. 
Procedures 
Questionnaire Mailing 
The survey design for this study entailed a transmittal letter 
and cp.!estionnaire mailed to orthopaedic medical device 
manufactures. The Director of Regulatory Affairs or the person 
responsible for filing section SlO(k)s for the company was asked 
to complete the questionnair~ and return it in a self-addressed, 
stamped envelope. 
The sample consisting of 27 different orthopaedic device 
categories was drawn from a population of over 245 orthopaedic 
device categories. These 27 device categories represented 5 Class 
I devices, 21 Class II devices and 1 Class III device. Figure 1 
below details the orthopaedic device classification category 
supplied in The 510lk) Register and the FDA device classification 
provided in the Federal Register (1987). 
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Figure 1 
Orthopaedic Device Classification Category 
and 
FDA Device Classification 
Dav!ca category DBV'ica Classification 
Operating Roam Accaascriaa 
Bena Fixation Plata 
Arthrcaccpe 
F~tibial, Sami-ccnstrained !:nae Prosthesis 
Intramedul.lary Fixation Red 
Ren-powered Fixation Apparatua 
Famcrotibial, ll0n-c011Btrained Xn- Prosthesis 
Pnelllllatic Pcwaxad Surgical I11Btrumant 
Forceps 
Smccth P:ixaticn Pill 
Orthopaedic cutting I11Btrulllallt (Saw) 
Bena Pixaticn Screw 
AC Pawarad Meter Surgical Instrument 
Limb Brace Orthcsis 
Cast, Ba.ndage 
Semi-ccnstraillad Elbcw Prosthesis 
Semi-constrained Bip MatallPcly Prosthaais 
Semi-co11Btrailled Bip Matal/Acatabular Prosthesis 
Invasive Traction Ccmpcrumt 
Semi-constrained !:nae Patallc/famcrotibial Prosth-is 
DC Pcwared Surgical IllBtrumellt 
Combined llail/BlaclalPlata Fixation Appliance 
Bemi-famcral !lip Metal Prosthaaia 
Interl.am:l.nar Spinal Fixation Appliance 
R011-c0nstrained, C11111m1tad Shoulder Prosthesis 
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The listing above constituted 553 devices manufactured by 148 
different companies from 1976 to 1987. This sample was drawn from 
over 950 orthopaedic devices manufactured by over 670 orthopaedic 
medical device manufacturers. The rationale for this sample 
selection was based on a selection criteria that the device 
category have a minimum of ten companies manufacturing devices 
between 1976 and 1988. The Sl0(K) Register lists all submissions 
by device category since 1976. A curso~ review of this document 
would reproduce with minimal computation this same list of 
evaluated categories. 
One hundred and six of the 148 device manufacturers were sent 
questionnaires. Contact with 42 manufacturers was not established 
due to relocation, non-existence, or insufficient information. 
Completed questionnaires were returned to the University of San 
Diego. 
Data Collection and Follow-up 
Within approximately two months, 28 questionnaires were 
returned for a return rate of 26%. Useful information was available 
on 24 of those 28 returned forms. Among those four returned forms 
with unusable information, the most common reason given for lack 
of response was the respondent's feeling that he or she could not 
supply appropriate information. Since the return of 24 forms 
represented only 128 device submissions between 1976 and 1987 for 
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a follow-up rate of 23%, further information was sought through 
phone interviews. 
The phone interview process was structured so that only one 
independent interviewer was utilized. A phone contact scenario was 
constructed which facilitated the gathering of information similar 
to that obtained on the mailed questionnaire. Phone interviews took 
4 - 5 minutes to complete. Approximately 8 - 10 hours were devoted 
to the phone interview process. Less than 5% of those contacted 
refused to participate in the study. Most participants were on the 
East Coast and unavailable for interview because of conflicting 
time frames, other obligations, or vacations. 
An additional. 15 mcm.ufacturei:s were contacted via the phone. 
This sample was drawn from the remaining 78 manufacturers who did 
not return the original mailing. The remaining 78 companies were 
prioratized based upon the number of submissions they had made 
between 1976 and 1987. This process was randomized in that not all 
subjects were contacted directly upon the first phone call. If a 
respondent was not reached upon the first call, he or she was not 
called again until the last subject on the list had been called. 
The list was then initiated again from the beginning. 
The questionnaire mailing and the phone interviews combined 
to produce 39 completed questionnaires with a return rate of 37%. 
This also increased the device submission number to 263 for a 
return rate of 47.5%. 
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The Research Approaches and Data Analysis 
Approach I 
The first level of analysis dealt with Research Question 
Number l. The research approach was a descriptive-correlational 
survey" !'t= purpose was to dete?:mine the relationship between three 
characteristics of the orthopaedic medical device manufacturing 
company and time to equ.ivalence. Fox ( 1969 J stated that a 
~orrelational aurvey was ~a survey designed to estimate the extent 
to which different variables are related to each other in the 
population of interest". 
Least square regression coefficients were developed based upon 
the straight-line relation between two variables summarized in the 
following equation: 
y = B0 + B1:c + s • 
In an effort to better represent how the dependent variable 
related to the independent variables, a curvilinear model was also 
developed. Polynomial equations and quadratic models were 
represented by: 
y = b 0 + b 1z + b~ 
These analyses were stratified by year, if data permitted. 
The Appendix o surnrnari.zes the hypotheses related to Research 
Question Number 1. 
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Approach II 
The second phase of the analysis addressed Research Questions 
2 and 3. This analysis compared 2 to 5 levels of 10 independent 
variables with one independent variable, t;me to equivalence. Since 
all comparisons involved two or more groups, one-way analysis of 
variance (ANOVA) was utilized to detect differences between groups 
or independent variable levels. 
ANOVA involved deciding if the variation due to differences 
between groups was larger than would be expected by chance. If the 
error variation represented the natural variation that would be 
expected with chance, and if the variation between groups was large 
relative to the error variation, the group means were likely to be 
different. 
However, the assumptions underlying the F-distribution of the 
ANOVA were not met in most comparisons. When the assiwptions 
underlying ANOVA were tested, it was determined that data 
imbalances and group variances existed for most groups. As a 
result; the ANOVA analogue, the Kruskal-Wallis test was used. 
Kruskal-Wallis chi-square approximations were t.~a:ited for each 
analysis of variance. 
These analyses were stratified by year! if data permitted. 
Appendix E summarizes the hr.;,ot,neses related to Research 
Questions 2 and 3. 
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Approach III 
This applied to Research Question Numbers 4. This third level 
of analysis was the statistical task of calculating regression 
coefficients and beta weights. Since the regression coefficients 
could not be compared against one another in an attempt to 
determine which of the various predictor variables was the best 
predictor variable, converted beta weights were computed. Beta 
weights were determined for each predictor vari~~le. The predictor 
variable that had the largest beta weight, disregarding whether the 
beta weight was positive or negative, was the best predictor. 
Significance levels were established at 0.05 when evaluating 
if a particular beta weight wa.s different from zero. If a 
particular predictor variable was not helping very much to decrease 
the difference between the predicted and actual criterion scores, 
then the beta weight for this predictor variable will be close to 
zero. 
This analysis was restricted to information representing the 
most recent company status. Therefore, comparisons were made for 
1987 only. 
Appendix F summarizes the hypotheses related to Research 
Questions 4. 
Approach IV 
This fourth level of analysis was primarily descriptive. It 
addressed information supplied through questions 4 and 10 on the 
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questionnaire. These questions requested the respondent supply 
opinion information. This yielded data which was qualitative in 
nature and nominal on type. 
Frequency tables were generated. Tendencies were evaluated 
through imposed stratifications relating to the following 
conditions: number of years manufacturing medical devices, number 
of employees in the organization, number of devices manufactured, 
presence of an in-house regulatory department, use of outside 
regulatory consul~ants, and regulatory training experiences. 
All statistical analysis, runs, tables and graphs are produced 
through PC based SAS statistical package. The SAS procedures which 
wex-e employed were FREQ, REG, ANOVA, and NPARlWAY. 
Criteria for Data Sources 
Several criteria were used to select data sources and include 
the following: 
Criteria 1. Documents have to be related to orthopaedic medical 
device firms in the United States. 
Criteria 2. Selected device categories have no less than ten 
devices manufactured between 1976 and 1988. 
Criteria 3. Selected firms have a regulatory affairs department and 
manager or some person responsible for regulatory affairs. 
Criteria 4. The person within each firm to whom the request for 
data was addressed was the regulatory affairs manager or person 
responsible for filing Sl0(k)s. 
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Surnrnary 
The chapter presented the methodo!ogy by which the research 
design was produced. The study examined the relationship among 
three independent variables and one dependent variable~ time to 
equivalence. The study further compared differences between twelve 
independent variables and one depenc!E:;r.t variable, time to 
equivalence. Data were collected from a population of small and 
large orthopaedic medical dev·ice manufacturing companies dispersed 
throughout the United States. 
To accomplish the study, a mailed, researcher-designed 
questionnaire was used. Phone interviews were also employed to 
facilitate follow-up and clarify subject responses. Validity and 
reliability of the instrument were discussed based upon a pilot 
study conducted to determine necessary changes in the instrument. 
The procedure of the experiment was specified in this chapter 
and the steps which achieved selection of firms for the study were 
outlined. Delineation of the data collection process and follo,;1-
up rates was provided. 
This chapter concluded witn designation of the four research 
approaches and data criteria which guided the statistical analyses 
in this study. 
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DATA ANALYSIS 
Time To Equivalence 
The chapter presented an analysis of data relative to the 
relationship of three elements of the independent variables, 
organizational costs and resource consumptions, and one dependent 
variable, time to equivalence (days). These relationships were 
evaluated over time. Further analysis included the measurement of 
mean differences in time to equivalence for five elements of the 
independent variable, organizational characteristics. Additional 
analysis was performed relative to the mean scores of the dependent 
variable, time to equivalence, and the five independent variables, 
five classes of attitudes toward perceived influences on time to 
equivalence. The relationship relative to all twelve elements of 
the independent variable, organizational characteristics, and the 
dependent variable, time to equivalence, were also analyzed. The 
last analysis with regard to the respondent's perceived influences 
on timely compliance was descriptive in nature. 
These analyses were made for the five research questions. For 
the first question regarding the relationship of time to 
equivalence and organizational costs and consumptions a regression 
line was fit to describe the relationship. For the second question 
regarding differences in time to equivalence relative to specified 
company characteristics, comparative analysis was performed over 
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time. The third question germane to time to equivalence and five 
classes of attitudes also involved comparative analysis. The fourth 
question required regression coefficients be converted into beta 
weights to best predict time to equivalence. The five question 
entailed frequency distributions of perceived influences on time 
to equivalence. 
Unit of Analysis 
Although s~rvey research provided techniques for examining 
practically any unit of analysis, typically such units were 
persons • Nevertheless, numerous surveys ~ave been conducted in 
order to gather information from iI&dividuals or "informants" about 
organization-level variables such as strategy or prof it influences. 
Venkatraman and Grant (1986) have identified two approaches 
that have been commonly adopted for operationalizing organization-
level constructs. One approach was the collection of data f~om a 
designated executive with an implicit assumption that the responses 
reflect organizational characteristics of interest. The second 
approach suggested the collection of data from multiple respondents 
from which the mean was calculated to represent an organizational 
score. 
This study utilized the first approach suggested above. The 
Director of Regulatory Affairs or the executive responsible for 
filing section Sl0(k)s was the designated subject who supplied 
responses. 
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Medical Device Categories 
The questionnaire and phone interview processes resulted in 
the return distribution illustrated in Figure 2 below. The device 
categories were listed in the sequence provided through the 510(kl 
Register. The second column in Figure 2 headed by Comp. represented 
the number of companies with device submissions to FDA in each 
device category. The third column headed Sub.listed the number of 
device submissions among the indicated companies and within a 
specified device category. 
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Figure 2 
Orthopaedic Medical Device Categories, 
Number of Companies, and 
Number of Device Submissions per Category 
Da,rice category Comp. Sul>. 
Operating Jlocm Accaaaoriaa l l 
Bona Fi=tion Plata 4 6 
Arthroscope 13 26 
F-,rotibial, Semi-con. Enaa Proathaais 7 22 
Intramadalluy Fixat1011 Rod 5 8 
•on-powered Fixation Apparatus 6 11 
F~tibiaJ., lion-con. Enaa Prostheaia 8 lO 
Pna11111atic Powarad Surgical Inatrm.nt 4 4 
Forceps 2 2 
s.xith Fixation Pin 2 2 
Orthopaedic cutting Inatrument (Saw) 2 2 
Bone Fixation Screw 6 7 
AC Powarad Mater Surgical Inatrm.nt 3 3 
LilDb Brace Orthosis l l 
cast, Bandage 2 2 
Sami-conatrainad Elbow Prosthesis 2 4 
Bemi-con. Hip MatallPoly Proatheaia 19 58 
e-1-con. Hip Matal/Acetabular Proa. 8 11 
Invasive Tracti011 C0111p0nm1t 4 8 
Sami-cona. ltnaa Patallo/Famorot.ibial Pro■• 11 27 
DC Powered Surgical Inatrwaant 2 2 
ec.l)ined !lllil/BladelPlata Pixat1011 Appl. 4 9 
Bemi-!emoral Hip Metal Prosthesis 9 15 
Iuterlaminar Sp1.nal. Fixation Appliance 3 4 
5011-conatrainad, Cemented Sllonlder Pro■• 5 9 
llaai-!amoral Hip MatallPol:ymer Proa. 7 8 
Cut Cclaponant 1 l 
Total 263 
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The above listing supplied information about the sample of 
companies in this study who made submissions from 1977 through 
1987. This represented a homogeneous sample of orthopaedic medical 
device categories. The purposive selection process provided for a 
fairly homogeneous sampling. In addition, selection bias did not 
seem tc influence the device distribution. 
The following section described the results of this 
investigation. All hypotheses were stated in the null, 
Results of Analysis 
Research Questions 
Research Question Number l 
What is the relationship between time devoted to establishing 
an FDA disposition of substantial equivalence for an orthopaedic 
medical device and related costs and resource consumption? 
Hypothesis 1.1. There is no relationship between time (days) 
needed to establish equivalence and the number of years a 
company has been manufacturing medical devices. 
The equation for the fitted straight line was: 
DAYS = b 0 + b 1 YEARS 
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Table 1 representd the results of the least square regression 
relating days tc the number of years manufacturing medical devices. 
The principle of least squares involved fitting a line through the 
points (i.e., days to equivalence) so that the vertical differences 
between all the points and the line were minimized. The "best" line 
was the line that minimized the sum of squared differences, hence 




Model Relating Variable DAYS TO EQUIVALENCE to 
Variable YEARS MA?Wf';..CTURING 
Intercept Slope S.E. a-square t-value P-value 
73.067 -0.345 0.108 0.038 -3.203 0.001• 
" - Signific11nt at 0.05 level 
The equation for the fitted straight line with the values from 
Table 1 inserted was now: 
Ti- to Equivalence(Days) - 73.067 + (-0.345)Years Manufacturing 
By completing this equation, it was apparent that 73.067 days 
was the predicted mean time to equivalence if zero was s..ibstituted 
for the number of yearia: manufacturing medical devices. This was the 
value of time to equivalence (days) at the point where the fitted 
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line intercepted the vertical axis. Under these circumstances, the 
intercept gave an estimate of the average number of days required 
to establit;h equivalence when a company had no manufacturing 
experience. The slope of the line was the amount of decrease in 
predicted days to equivalence that would result from an increase 
in one year of manufacturing experience. 
As a result, the predicted mean number of days to equivalence 
for a company manufacturing medical devices one year would be 
72.722 days. The predicted value for a company with five years of 
manufacturing experience would be 71.338 days. The predicted value 
for ten years experience would be 69.608 days. The predicted value 
of 42.277 days resulted when considering the oldest company in this 
study with 89 years manufacturing experience. 
The R-square value of 0.0378 indicated that little, if any, 
of the variation in the data was accounted for in the proposed 
model. This value also reflected a low level magnitude with regard 
to the relationship of d.ays to equivalence and ntilllber of years 
manufacturing. The low level R-square value indicated that other 
variables may have been needed in the equation to account for 
variation in the data. However, this finding does not contradict 
the significance of the relationship which was found to exist 
between the number of years manufacturing and days to equivalence. 
The analysis related to Research Question Number 4 below further 
illustrated the impact of other variables in the regression 
equation. 
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However, upper and lower 95% prediction limits were calculated 
to further elaborate on the magnitude of this relationship. These 
calculations allowed for bounds to be put around a single predicted 
value. These bounds gave a probable range for the number of days 
to equivalence that were required given the number of years 
manufacturing. The magnitude of the relationship was further 
enhanced through thess computations since the prediction limits 
took into account the variation in the dependent variable for 
observations with the same value of the independent variable. These 
limits also took into account any error in the fitted regression 
line. 
For example, a company with four years experience in 
manufacturing devices had an average predicted time to equivalence 
equal to 71.68 days. The 95% limits were -27.88 and 171.2 days. 
This meant that there was a 95% confidence level that the number 
of days to equivalence for a company with four years manufacturing 
experience was somewhere between -27.88 and 171.2 days. This wide 
of a range was a result of variation in days to equivalence values 
caused by factors othsr than the number of years manufacturing. 
Realizing the possible need for another term or factor in the 
regression model which would better represent the relationship 
between days to equivalence and number of years manufacturing, a 
quadratic regression equation was introduced to fit the curve. 
Table 2 below supplies the results of those computations. 
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Table 2 
Quadratic Model Relating Variable DAYS TO EQUIVALENCE 
to Variable YEARS MANUFACTURING 
df Intercept Slope S.B. R-aquare t-value P-value 
262 83.026 o.ooe o.oos 0.0473 1.609 0.109 
The quadratic model produced at-value for years (squared) 
equal to 1.609 and statistically significant at the 0.1088 level. 
This indicated that there was 1 chance in 10 of getting a t-
statistic as large as the one for years squared. This seemed to 
suggest there was no need for imposing the quudratic model to 
better represent the relationship between days to equivalence and 
number of years manufacturing. 
Although a low-level correlation seemed to exist between days 
to equivalence and number of years manufacturing, Table 1 did 
provide other =elevant information. The t-value of -3.203 with the 
probability of 0.0015 rejected the null hypothesis that the slope 
equaled zero. The p-value for the t-value of 0.0015 supplied 
evidence that tn~ slope was not zero. In other words, increasing 
the number of years manufacturing medical devices did produce a 
statistically significant decrease in the number of days required 
to reach equivalence. 
In conclusion, the null hypothesis was rejected in favor of 
the alternative that a relationship did exist between the number 
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of years manufacturing orthopaedic medical devices and the number 
of days required to establish equivalence. Albeit the correlation 
between number of years and days was equal to 0.194 and only 4% of 
the differences among the companies who manufa~tured medical 
devices in terms of years was predictable on the basis of 
differences in the days to equivalence, increasing the number of 
years a company manufactures medical devices did produce a 
statistically measurable decrease in the number of days required 
to establish that a medical device was equivalent to another device 
manufactured prior to 1976. 
Hypothesis 1.2. There is no relationship between time (days) 
needed to establish equivalence and tte number of employees 
in an organization. 
Table 3 represents the results of the least square regression 
relating days to the number of employees in the organization. This 
analysis was applied to the years 1977 through 1987. 
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Table 3 
Model Relating Variable DAYS TO EQUIVALENCE to 
Variable NUMBER OF EMPLOYEES IN ORGANIZATION 
rear df Intercept Sl~ S.E. t-value P-value 
1977 137 58.697 -0.003 0.010 -0.256 0.7981 
1978 194 53.713 0.015 0.001 2.295 0.0228• 
1979 194 54.083 0.015 0.001 2.330 0.0209• 
1980 217 58.026 0.014 0.001 2.183 0.0301* 
1981 217 58.997 0.014 0.006 2.100 0.0369* 
1982 220 60.653 0.015 0.006 2.211 0.0241"' 
1983 220 56.843 0.011 0.006 1.709 0.0888 
1984 227 60.652 0.010 0.007 1.332 0.1843 
1985 234 65.463 0.007 0.001 o.935 0.3509 
1986 240 63.196 0.006 0.007 0.856 0.3928 
1987 243 64.709 0.005 0.001 0.713 0.4763 
••Significant at o.os level. 
The data listed in Table 3 seemed to indicate that there 
existed a positive relationship between the number of employees in 
an organization and the number of days needed to establish 
~-qui valence. 'l'he only exception to this premise was in 1977 where 
there seemed to be a negative relationship. 
One possible reason for the existence of a negative 
relationship in 1977 was the fact that the 1976 amendment 
positioned both FDA and industry in an arena that was new for both. 
FDA was uneducated and did not require all regulatior_.3 be met; 
thus, establishing equivalence in a shorter period of time. 
Industry, realizing a «ood to satisfy new federal regulations, 
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employed more personnel to meet these new regulatory demands. 
Consequently, as the number of °"'Ployees rose, time to equivalence 
declined. 
Albeit, the years from 1978 to 1982 seemed to provide evidence 
at the 0.05 significance level that the pattern observed in 1977 
was being reversed: as the number of employees in a company 
increased so did the number of days needed to establish 
equivalence. Clarity regarding this trend was furnished again by 
the status of the agency and industry in unison. As the agency 
matured in its regulatory responsibilities, so did the requirements 
for compliance. This naturally increased the days to equivalence. 
The medical device industry, as mentioned above, continued to bring 
in more employees to meet the regulatory requirements. This 
increase in employees was seen in many departments other than the 
regulatory department. Those departments with new demands as a 
result of the 1976 amendment were: manufacturing, quality 
assurance, Research and Development, advertizing, sales, and 
marketing. 
Statistically significant relationships declined or were non-
existent from 1982 t~ 1987. In fact, the relationship seemed to 
progressively decline as each year passed. The rationale for this 
I6v~latica rested primarily with industry at this juncture. FDA 
continued to make regulatory requests for compliance and, as a 
result~ time to equivalence increased. However, industry 
departments became saturated and discovered that continued employee 
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recruitment was not reducing time to equivalence. 
Consequently, the null hypothesis was rejected from 1978 
through 1982. A positive relationship existed between time to 
equivalence and the number of employees in an organization. From 
19i8 to 1982, organizational employee size increased as did time 
to equivalence. The null hypothesis was retained from 1982 to 1987. 
The number of employees in the organization did not have a 
statistically significant impact time to equivalence. 
Hypothesis 1.3. There is no relationship between time (days) 
needed to establish equivalence and the number of employees 
in the regulatory department. 
Table 4 represents the results of the least square regression 
relating days to the number of employees in the regulatory 
department. This analysis was applied to the years 1977 through 
1987. 
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Table 4 
Model Relating Variable DAYS TO EQUIVALENCE to 
Variable NUMBER OF EMPLOYEES IN THE REGULATORY DEPARTMENT 
Year df Intercept Slope S.B. t-value P-value 
1977 137 58.446 -0.451 1.042 -0.433 0.6658 
1978 194 56.471 -0.245 1.088 -0.225 0.8223 
1979 194 56.888 -0.423 1.145 -0.369 0.7124 
1980 217 60.218 -0.926 1.035 -0.894 0.3721 
1981 217 61.092 -1.092 1.049 -1.041 0,2991 
1982 220 62.277 -1.275 0.977 -1.305 0.1933 
1983 220 59.974 -0.885 0.982 -0.901 0.3685 
1984 227 63.794 -1.305 1.020 -1.279 0.2021 
1985 234 67.870 -1.813 1.014 -1.789 G,0749 
1986 240 65.444 -1.495 0.986 -1.515 0.1310 
1987 243 66.804 -1.576 0.938 -1.680 0,0942 
Review of Table 4 indicated that the number of days required 
to reach equivalence seemed to increase with time. There was no 
consistent evidence that there existed a relationship between the 
number of employees in a regulatory department and the number of 
days necessary to get a medical device through the regulatory 
review precess. 
Years 1985 and 1987 were the only years in which increasing 
the number of employees in a regulatory department seemed to 
significantly, although not statistically significant, decrease at 
the .10 level the number of days to equivalence. Although not 
statistically significant, the number of employees in a regulatory 
department did seem to negatively impact the number of days to 
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equivalence at every time interval. In other words, it seemed 
apparent that an increase in the number of employees in the 
regulatory dep~ent resulted in fewer days required to establish 
equivalence. As time went on, regulatory employees increased and 
time to equivalence (days) decreased. This would seem to suggest 
that the time required to get a device through the FDA review 
process may be decreased by increasing the number of employees in 
the regulatory department. 
Research Question Number 2 
Is there any difference between respondents (companies) who 
possess or do not possess certain identified characteristics and 
time required to establish equivalence? 
Hypothesis 2.1. There is no difference between the type of 
medical device manufactured and time to equivalence. 
Since the assumptions of normality and homogeneity of the 
parametric F-test were not met for this hypothesis, the Kruskal-
Wallis test was utilized in an effort to make the study findings 
more generalizable. The Kruskal-Wallis test assumes that the 
variables under study have an underlying continuous distribution 
and are measured on at least an ordinal level. The results of that 
analysis is provided in Table 5. 
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Table 5 
Wilcoxon Scoras (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable TYPE OF DEVICE 
Class N Expected Std Dev 
Class I 245 32340.0 265.12 
Class II 15 









Kruskal-Wallis Test (Chi-Square Approximation) 
CHISQ = 2.9543 df = 2 Prob> CHISQ = 0.228 
The null hypothesis was retained. The calculated chi-square 
value did not exceed the critical value at the predetermined level 
of significance (0.05). There did not appear to be a difference 
between the type of medical devices manufactured and the number of 
days needed to establish equivalence. 
Inspection of the data seemed to indicate that Class I devices 
had a lower mean days to equivalence than Class II devices; 
however, not statistically significant. Since there were only three 
Class III submissions within our sample, the mean value was 
suspect. However, this pattern was not aberrant since the 
proportion of submissions within the total population was 
approximately distributed as represented in Table 5. 
The chi-square value of 2.95 with prob> 0.228 was less than 
the reference probability value of 0.25. Therefore, there was a 25% 
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chance that whatever difference that existed between the types of 
medical devices as they related to days to equivalence was not due 
to random error. Thus, whatever differences that seemed apparent 
did not signify genuine population differences. 
The nonparametric analogue, Kruskal-Wallis tests were 
performed for the following hypotheses related to Research Question 
Number 2. Tables 6 through 9 detail the results of that analyses. 
All comparisons were stratified by years 1977 through 1987. 
Hypothesis 2 • 2 • There is no difference between companies 
having in-houae _regulatory departments and companies that 
don't have in-house regulatory departments on time to 
equivalence. 
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Table 6 
Wilcoxon Scores (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable REGULATORY DEPARTMENT 
Yellr Clua B Mean df CBISQ Prob>CHISQ 
1977 Yea 203 127.49 1 3.12 0.077 
Bo 60 147.25 
1978 Yes 203 127.49 1 3.12 0.011 
Bo 60 147.25 
1979 Yes ~04 126.88 1 4.11 0.043* 
Bo 59 149.67 
1980 Yes 225 130.11 1 0.96 o.328 
Bo 38 143.16 
1981 Yes 225 130.11 l 0.96 0.328 
Ro 38 143.16 
1982 Yes 228 o.•29.96 l 1.23 0.268 
Bo 35 145.36 
1983 Yes 228 129.96 l 1.23 0.268 
Bo 35 145.36 
1984 Yes 235 130.51 1 o.85 0.358 
Bo 28 144.50 
1985 ~es 241 131.21 1 0.31 c.s1e 
Bo 22 140.64 
1986 Yes 247 129.87 ! 3.19 0.074 
Bo 16 164.91 
1987 Yes 251 13C.51 1 2.11 0.146 
Bo 12 163.17 
••Significant at 0.05 level. 
The years 1977 and 1978 had significant differences, although 
not statistically significant, between groups at the .10 level. 
Furthermore, the difference in mean days to equivalence was 
statistically significant at the .OS level in 1979. 
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There appeared to be one primary reason for this finding. In 
an effort to meet the new regulatory requirements and stay 
competitive during the initial years of the 1976 amendment 
enactment, the medical device industry heavily recruited regulatory 
professionals from within the pharmaceutical industry. These 
individuals had experience and had an immediate impact on time to 
equivalence. In addition, the larger companies were more successful 
in their recruiting endeavors since they could afford the more 
talented regulatory professional. The experience which transferred 
from the drug environment culminated after approximately three 
years which resulted in a statistically significant difference in 
1979. 
This level of significance did not emerge again until 1986 
when the number of companies that did not have a regulatory 
department declined to 16 from 60 in 1977. In addition, the mean 
days to equivalence from 1977 to 1985 ranged between 140 and 150 
days for companies that did not have a regulatory department. 
However, in 1986, the mean days rose to nearly 165 days. This would 
seem to account for the significance level of .07 being detected. 
No industry or FDA circumstance was readily apparent during this 
time frame. 
The null hypothesis was retained at the • 05 significance level 
for all comparisons, except 1979. The number of days to equivalence 
appeared to be independent of the presence or absence of an in-
house regulatory department for all years aside from 1979. 
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Thus, companies with regulatory departments in-house produced 
statistically significant reductions in the time required to 
establish equivalence in 1979 only. 
Hypothesis 2.3. There is no difference between companies who 
received regulatory compliance training and companies who 
didn't receive regulatory compliance training on time to 
equivalence. 
Table 7 below reflects the results of testing hypothesis 2.3 
by years 1977 through 1987. 
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Table 7 
Wilcoxon Scores (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable REGULATORY TRAINING 
Year Class R Mean df CBISQ Prob>CBISO 
1977 Yea 153 126.75 1 1.74 0.187 
Ro 7,;;o 139.40 
1978 Yea 1"' ,., 126.75 1 1.74 0.187 
Ro 1.10 139.40 
1979 Yes 189 124.21 1 7.04 0.008* 
Ro 74 151.88 
1980 Yea 189 124.21 l 7.04 0.008* 
Ro 74 151.88 
1981 Yea 210 128.43 l 2.30 0.129 
Ro 53 146.16 
1982 Yea 213 128.29 1 2.67 0.102 
Ro so 147.81 
1983 Yes 214 128.35 1 2,64 0.104 
Ro 49 147.92 
1984 Yes 221 130.59 1 0.48 0.490 
Ro 42 139.43 
1985 Yes 226 131.41 1 0.10 0.755 
Ro 37 135.62 
1986 Yea 226 131.41 1 0.10 0,755 
Ro 37 135.62 
1987 Yes 226 131.41 1 0.010 0.755 
Ro 37 135.62 
••Significant at o.os level. 
Upon review of the data regarding hypothesis 2.3, there did 
not appear to be a difference in group means regarding the number 
of days to equivalence. It appeared that regulatory training did 
not have a statistically significant impact on time to equivalence. 
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The only years that did not adhere to this finding were 1979 and 
1980. 
Comparing groups did yield a .008 lsvel of significance for 
1979 and 1980. It was evident that there had been a 33% decrease 
from 1978 to 1979 in companies who had not receiv~d regulatory 
training. In addition, the mean days to equivalence had increased 
by 8% from 1978 to 1979 for those companies with regulatory 
training. This pattern remained constant through 1980. From 1981 
through 1987 the difference between means remained negligible. 
Once again, some reasons for this occurrence resided in the 
industry and the agency. For the industry, the years 1S77 and 1978 
amounted to lead years where regulatory knowledge was being accrued 
at a fast rate, but with little consequence. Also, during these 
years, the agency was in a developmental stage with regard to 
whatever regulatory training that was being provided. The agency 
was just beginning to orient the Off ice of Small Manufacturers 
Assistance (OSMA) to the needs of the medical device manufacturer. 
In fact, the first article highlighting the services provided by 
DSMA was published in 1979. This event may partially explain the 
significance achieved in 1979 and 1980. 
The reduced difference from 1981 through 1987 reflected the 
diffusion of the body of experience that was attained during 1979 
and 1980. The level of skill across the industry became diluted and 
a fairly homogeneous group emerged with regard to regulatory 
knowledge. The arrival or departure of a trained regulatory 
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professional did not have a statistically significant impact on 
time to equivalence from 1981 through 1987. 
Therefore, days to equivalence seemed independent of 
regulatory training experience except in 1979 and 1980. The null 
hypothesis was rejected for these years only. During 1979 and 1980, 
regulatory training did have a statistically significant influence 
on time to equivalence. 
Hypothesis 2.4. There is no difference between companies who 
manufacture one medical device and companies that manufacture 
more than one device on time to equivalence. 
Table 8 below reflects the results of testing hypothesis 2.4 
by years 1977 through 1987. 
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Table 8 
Wilcoxon Scores (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable MORE THAN ONE DEVICE 
Year Claaa B Nean DP CHISQ Prob>CBJ:SQ 
1977 Yea 216 124.55 1 11.61 0.0007• 
Bo 47 166.24 
1978 Yes 216 125.55 1 11.61 0.0007• 
Bo 47 166.24 
1979 Yes 216 124.55 1 11.61 0.0007• 
Bo 47 166.24 
1980 Yes 237 127.75 1 7.49 0.006• 
Bo 26 170.75 
1981 Yes 24"j 129.25 1 4.98 0.026• 
Bo 17 171.82 
1982 Yes 249 129.12 1 6.70 0.010• 
Bo 14 183.21 
1983 Yea 250 129.58 1 5.12 0.024• 
Bo 13 178.54 
1984 Yea 254 130.59 1 2.56 0.109 
Bo 9 171.89 
1985 Yes 255 130.35 1 3.94 0.047• 
Bo 8 :i.84.56 
1986 Yes 259 130.97 1 s.12 0.077 
Bo 4 198.62 
1987 Yes 260 130.91 1 4.72 0.030• 
Bo 3 226.83 
••Significant at 0.05 level 
Table 8 indicates that there was a difference at the .10 level 
between groups for all years investigated. In fact, that difference 
was very apparent from 1977 through 1983 where the significance 
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exceptions to that finding. 
Time to Equivalence 
Years 1984 and 1986 were the only 
The difference between means and the decline in the number of 
companies manufacturing only one device was noteworthy. From 1977 
through 1979 the average difference in means was 42 days while the 
number of companies manufacturing only one device remained constant 
at 47. In 1980, the number of companies who reported manufacturing 
only one device declined by 45% to 26; however, the difference in 
means rose only 2% to 43 days. 
This observed decline in companies manufacturing only one 
device, minimal change in mean day differences, and decline in 
significance level was also observed in 1981 and 1983. In 1982, the 
significance level again rose to 0.009 which seemed to be explained 
by an increase in time to equivalence over 19 81 for companies 
manufacturing only one device. 
In 1984, there was a decline in days to equivalence for 
companies manufacturing one device and a slight increase for those 
manufacturing more than one device; thus, the reason for the 
attainment of a non-significant level. In 1986, no decline was 
seen, however. The achieved significance level of O. 078 may be 
explained by the small sample size during this year. Although 1987 
also had a small sample size, the increase in days to equivalence 
for companies manufacturing one device was much more pronounced 
when compared to 1986 (12% vs. 7%). 
Throughout the years 1977 - 1987, the range of days to 
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equivalence for companies manufacturing more than one device was 
124 in 1977 to 131 in 1987. However, the range for companies 
manufacturing only one device was 166 days in 1977 to 226 days in 
1987. 
Another agency perspective which provided insight to the 
attained significance levels in 1984 and 1986 was the introduction 
of more stringent regulatory requirements during 1984 and 1986. The 
Medical Device Reporting (MDR) law was put into effect in late 
1984. This law required all companies to report all device defects 
which may have had an adve=se effect on the health and safety of 
the patient. Never before had such reporting been required nor in 
such a structured manner nor with such striking consequence. The 
anticipation and enactment of such a law may have neutralized any 
difference in days to equivalence for the two groups for this 
comparison. 
Thus, the null hypothesis was rejected at the .OS level for 
all years other than 1984 and 1986. The number of days to 
equivalence was dependent on the number of devices a firm 
manufactures. The company characteristic of manufacturing one 
device versus manufacturing more than one device did seem to have 
an impact on time to equivalence over time. Those companies that 
manufactured more than one device accumulated fewer days of time 
to equivalence as compared to companies who manufactured only one 
device. 
Hypothesis 2.5. There is no difference between companies who 
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r·eport using regulatory affairs consul tan ts and companies that 
ti~n't use regulatory affairs consultants on time to 
equivalenC""". 
Table 9 below reflects the results of testing hypothesis 2.s 
by years 1977 through 1987. 
Table 9 
Wilcoxon Scores (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable RB6ULATORY CONSULTANT USE 
Year Class H Mean df CBISQ Prob>CBISQ 
1977 Yea 142 122.15 l 5.71 0.020• 
Ho 121 143.55 
1978 Yea 145 121.61 l 6.02 0.014• 
Ho 118 144.57 
1979 Yea 147 120.83 l 7.17 0.007• 
Bo 116 146.14 
1980 Ye& 178 128.38 l 1.24 0.264 
Ho 85 139.58 
1981 Yea 186 131.00 l 0.11 0.742 
Bo 77 134.40 
1982 Yes 189 130.80 l 0.16 0.685 
BO 74 135.04 
1983 Yes 177 128.99 l 0.85 0.357 
Bo 86 138.19 
1984 Yes 155 123.72 l 4.47 0.034• 
50 108 143.88 
1985 Yes 126 129.45 l 0.30 0.586 
Bo 137 134.45 
1986 Yes 129 131.60 l 0.007 0.933 
Ho 134 132.28 
1987 Yea 129 131.60 l 0.007 0.933 
Ro 134 132.38 
••Significant at 0.05 level. 
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From 1977 to 1982 the use of regulatory affairs consultants 
was on the incline. From 1983 to 1987, the use of consultants 
declined. 
From 1977 to 1980 a statistically significant difference was 
found to exist between groups at the .OS level. This significance 
level progressively declined from 1980 t.:iiL"o-~gh 198~, when 
consultant use was the highest. In 1984, when consultant use 
started to balance out with non-use, a statistically significant 
cifference ( p > 0.05) was detected again. However, as the 
discrepancy between use and non-use diminished from 1985 through 
1987, so did the difference in days to equivalence. 
Patterns which emerged within the industry and agency as 
expressed earlier were seen here as well. In an effort to stay 
competitive within the newly regulated ma,ketplace, the medical 
device manufacturer brought in outside regulatory consultants from 
1977 through 1982. This newly instituted workforce had a 
statistically significant impact on time to equivalence in 1977. 
This influence increased from 1978 through 1979. In 1979, where the 
greatest significance level was attained, it was apparent that the 
use of outside regulatory consultants was producing a profound 
impact on time to equivalence. 
As seen before, once the industry acquired internal regulatory 
expertise through training and new employees, use of consultants 
was less influential. After 1979, FDA was perfecting its training 
programs and dissemination of information. Al though consultant use 
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did not decline from 1980 through 1S83, no statistically 
significant difference in time to equivalence was detected. This 
lack of significance was possibly due to consultant activities 
devoted to keeping up with more stringently imposed older 
regulations. Whereas, in 1984, when significance was seen again, 
consultant use, al though on the decline, was being applied in 
response to new regulations (e.g., MOR law). 
In conclusion, it seemed apparent that early (1977 - 1979) 
consultant use may have contributed to reduced days to equivalence. 
Albeit, as the number of days to equivalence increased and 
consultant use declined, the impact on time to equivalence was less 
measurable. In other words, early differences in time to 
equivalence may have been dependent on use of regulatory affairs 
consultants. The more recent trend, however, indicated 
that days to equivalence was independent of consultant use. 
Thus, the null hypothesis was rejected at the .OS level of 
significance for years 1977 - 1979 and 1984. 
Research Question Number 3 
Is there a any difference between time to equivalence and 
respondent's (company's) attitudes about selected characteristics 
of the regulatory process as having an impact on time to 
equivalence? 
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Since the assumptions of normality for an ANOVA were not met 
for this research question, hypotheses 3.1 through 3.5 were tested 
via the Kruskal-Wallis test. Tables 10 - 14 supply information 
related to these tests. 
In Tables 10 - 14, the comparison between groups reflec·:.:ed 
information related to classes or levels of the independent 
variable. Class 1 equals "Strongly Agree". Class 2 equals "Agree". 
Class 3 equals "No Opinion". Class 4 equals "Disagree". Class 5 
equals "Strongly Disagree". 
Hypothesis 3.1. There is no difference between the companies 
who perceive FDA written communication as having an impact on 
timely compliance and companies that don't perceive FDA 
written co:mrmmication as having an impact on timely compliance 
on time to equivalence. 
Table 10 highlights the results of testing hypothesis 3.1. 
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Table 10 
Wilcoxon Scores (?.ank Sums) for Variable DAYS 
TO EQUIVALENCE Class~fied by Variable ATTITUDE 
TO'WARD WRITTEN COM.MUNICATION WITH FDA 
Class N Mean Score 
Strongly Agree 22 161.20 
Agree 137 116.64 
No Opinion 5 131.50 
Disagree 94 143.69 
Strongly Disagree 5 205.10 
Kruskal-Wallis Test (Chi-Square Approximation) 
CHISQ=lS.667 df=4 Prob> CHISQ=0.003 
Since the calculated value of the test statistic exceeded the 
critical value at the O. 003 level, th&re was a statistically 
significant di£ ference between the various levels of agreement 
regarding written communication with FDA and time to equivalence. 
The null hypothesis was rejected. In conclusion, the 
difference in average days to equivalence for the five levels of 
agree!dent regarding written communication with the FDA was 
statistically significant at the 0.003 level. There was a 
diff~:rence in mea."l days to equivalence between companies who 
perceived written communication with FDA as having an impact on 
timely compliance and companies who did not perceive written 
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communication with FDA as having an impact on timely compliance. 
Review of Table 10 indicated that those respondents who agreed 
that written communication with FDA impacted time to equivalence 
had the lowest mean time to eq-.iivalence ( 116 days) and the greatest 
number of respondents (n = 137) • The next highest group of 
respondents (n = 94) disagreed with the tenet that written 
commu..~ication impacted time to equivalence and their mean time to 
equivalence was 131 days. Those respondents who strongly disagreed 
with the influence of written communication had the highest mean 
value of 205 days to equivalence. It was interesting to note that 
those respondents who strongly agreed with this influence had the 
second highest mean time to equivalence ( 161 days) • This may 
indicate that extensive written communication with FDA results in 
delays associated with numerous channels of communication, 
interfacing review bodies, bureaucratic levels, and the logistics 
of generating and logging official communications with FDA. 
Hypothesis 3.2. There is no difference between companies who 
perceive FDA oral communication as having an impact on timely 
compliance and companies that don't perceive FDA oral 
communication as having an impact on timely compliance on time 
to equivalence. 
Table 11 highlights the results of testing hypothesis 3.2. 
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Table 11 
Wilcoxon Scores (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable ATTITUDE 
TOWARD ORAL COMMUNICATION WITH FDA 
Class N Mean Sccre 
Strongly Agree 28 160.05 
Agree 154 129.00 
No Opinion 5 118.90 
Disagree 76 128.60 
Strongly Disagree 0 000.00 
Kruskal-Wallis Test (Chi-Square Approximation) 
CHISQ = 4.349 df=3 Prob> CHISQ = 0.226 
Since the calculated value of the test statistic did not 
exceed the critical value at the 0.05 level, there was no 
measurable difference between the different levels of agreement 
regarding oral communication with FDA and time to equivalence. 
Although over 69% of the respondents were of the opinion that 
oral communication with FDA did impact time to equivalence, there 
did not appear to be a statistically measurable difference in time 
to equivalence. It was noteworthy that those individuals who 
disagreed with this hypothesis had second lowest mean value. In 
addition, those r.8spondents with no opinion about this influence 
on time to eqi~ivalence had the lowest mean days. This finding was 
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difficult to assess due the low number of respondents in this 
category. 
The null hypothesis was retained. Thus, the difference in 
average days to equivalence for the five levels of agreement 
regarding oral communication with the FDA was not statistically 
significant different at the 0.05 level. There was no statistically 
significant difference in mean days to equivalence between those 
companies who perceived oral communication with FDA has having an 
infl11ence on timely compliance and those companies who did not 
perceive oral communication as having an impact on timely 
compliance. 
Hypothesis 3.3. There is no difference between companies who 
perceive the Office of Small Manufacturers Assistance (OSMA) 
regulatory compliance training as having an impact on timely 
compliance and companies who don't perceive the OSMA 
regulatory compliance training as having an impact on timely 
compliance on time to equivalence. 
Table 12 has the results of testing hypothesis 3.3. 
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Table 12 
Wilcoxon Scores (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable ATTITUDE 
TOWARD REGULATORY TRAINING 
Class N Mean Score 
Strongly Agree 27 137.05 
Agree 158 128.99 
No Opinion 24 125.77 
Disagree 53 141.34 
Strongly Disagree 1 125.00 
Kruskal-Wallis Test (Chi-Square Approximation) 
CHISQ = 1.335 df=4 Prob> CHI~Q = 0.855 
Since the calculated value of the test statistic did not 
exceed the critic al value at the 0. 05 level, there was no 
statistically measurable difference between the various levels of 
agreement regarding regulatory training experience and time to 
equivalence. 
Again, the majority of the respondents (70%) agreed that 
regulatory training did impact time to equivalence, but the 
difference in mean values were not statistically significant. The 
highest mean values were recorded for those respondents who were 
of the opinion that regulatory training did not impact time to 
equivalence (141 days). 
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Due to the large number of respondents (n = 24) who had no 
opiniou about this influence, a 2x3 contingency table was 
generated. A dichotomous category of agree and disagree was 
crosstabulated with three levels of days (i.e., 0-50, 50-100, and 
greater than 100 days). Those respondents with no opinion were 
collapsed into the disagree ca~egc:ry to assure a conservative 
interpretation of the results. Table 13 presents the results of 
that crosstabulation. A non-significant result was achieved for 
this test of difference between the observed number and the 
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The null hypothesis was retained. In conclusion, the 
difference in average days to equivalence for the five levels of 
agreement regarding regulatory training was not statistically 
significant at the 0.05 level. The collapsed crosstabulation was 
also not significant at the 0.05 level. It was apparent that the 
difference in time to equivalence was not statistically significant 
with regard to opinions related to regulatory training. 
Consequently, there was no statistically significant difference in 
mean days to equivalence between companies who perceived OSMA 
regulatory training as ha~·ing an influence on timely compliance and 
companies who did not perceive OSMA regulatory training as having 
an influence on timely compliance. 
Hypothesis 3.4. There is no difference between companies who 
perceive having an in-house regulatory department as having 
an impact on timely compliance and companies who don't 
perceive having an in-house regulatory department as having 
an impact on timely compliance on time to equivalence. 
Table 14 highlights the results of testing hypothesis 3.4. 
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Table 14 
Wilcoxon Scores (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable 
ATTITUDE TOWARD AN IN-HOUSE REGULATORY DEPARTMENT 
Class N Mean Score 
Strongly Agree 82 127.15 
Agree 174 134.53 
No Opinion 6 118.25 
Disagree 1 171.50 
Strongly Disagree 0 000.00 
Kruskal-Wallis Test (Chi-Square Approximation) 
CHISQ = 0.993 df=3 Prob> CHISQ = 0.803 
Since the calculated value of the test statistic did not 
exceed the critical value at the O. OS level, there was no 
statistically significant difference between the various levels of 
agreement regarding the presence or absence of an in-house 
regulatory affairs department and time to equivalence. 
Although 97% of the respondents agreed that an in-house 
regulatory department impacts time to equivalence, no difference 
in means was apparent. It was notable that there was a large 
difference in mean days to equivalence between those that agreed 
and those that disagreed. However, the small number of respondents 
who disagreed (n = 1) made this comparison questionable. 
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The null hypothesis was retained. In conclusion, the 
difference in average days to equivalence for the five levels of 
agreement regarding in-house regulatory departments was not 
statistically significant at the 0.05 level. That is, there was no 
statistically significant difference in mean days to equivalence 
between companies who perceived the presence of an in-house 
regulatory department as having an influence on timely compliance 
and companies who did not perceive having an in-house regulatory 
department as having an influence on timely compliance. 
Hypothesis 3.5. There is no difference between companies who 
perceive the use of outside regulatory affairs consultants as 
having an impact on timely compliance and companies that don't 
perceive the use of outside regulatory affairs consultants as 
having an impact on timely compliance on time to equivalence. 
Table 15 highlights the results of testing hypothesis 3.5. 
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Table 15 
Wilcoxon Scores (Rank Sums) for Variable DAYS 
TO EQUIVALENCE Classified by Variable ATTITUDE 
TOWARD REGULATORY CONSULTANT USE 
Class N Mean Score 
Strongly Agree . 4 138.55 
Agree 158 123.34 
No Opinion 64 131.48 
Disagree 16 177.44 
Strongly Disagree 21 162.88 
Kruskal-Wallis Test (Chi-Square Approximation) 
CHISQ = 11.25 df=4 Prob> CHISQ = 0.024 
Since the calculated value of the test statistic exceeded the 
critical value at the 0.05 level, there was a statistically 
significant difference between the various levels of agreement 
regarding the use of outside regulatory affairs consultants and 
time to equivalence. 
Only 61% of the respondents agreed that time to equivalence 
was impacted by use of outside regulatory consultants. Thirty-one 
percent were of no opinion and 8% of the respondents disagreed. The 
a ·erage mean value for those that agreed was 130 days. The average 
mean value for those that c~s~greed was 166 days. 
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As with hypothesis 3.3, a large portion of the respondents 
were of no opinion regarding this influence on timely compliance. 
A 2x3 contingency table was generated again with the no opinion 
responses being collapsed into the disagree category. Table 16 
highlights the results of this analysis. Although the chi-square 
statistic was not statistically significant at the 0.05 level, it 
was notable that the percentage of respondents who disagreed with 
this influence was twice that of those that agreed when beyond 100 
days to equivalence, 18.81% and 9.26%, respectively. This nr.Jn-
significant finding may be attributed to the conservativeness of 
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Based on the Kruskal-Wallis test statistic, the null 
hypothesis was rejected. In conclusion, the differencs in average 
days to equivalence for the five levels of agreement regarding use 
of regulatory affairs consultants was sta~istically significant at 
the O • 05 level. Thus, there was a statistically significant 
difference in mean days to equivalence between companies who 
perceived the use of outside regulatory consultants as having an 
impact on timely compli&nce and companies who did not perceive the 
use of outside regulatory consultants as having an impact on timely 
compliance. 
Research Question Number 4 
What combination of independent variable measures best 
predicts time to equivalence? 
The testing of research question number 4 involved looking at 
combined independent variables and how t.hose combinations predicted 
time to equivalence. Up to this poin·t concentration had been on 
predicting time to equivalence based on the following independent 
variables: number of years manufacturing medical devices, number 
of employees in the organization, and number of employees in the 
regulatory department. The question still remained as to what other 
variables may have also effected time to equivalence. Since this 
model involved multiple independent variables, a multiple 
regression prediction equation with conve:r'i::ed beta weights were 
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calculated. 
There were twelve independent variables in this equation, 
Xi- •• X12 • They were the following: number of years manufacturing 
medical devices (YEARS), number of employees in the organization 
in 1987 (EMP087), presence or absence of a regulatory department 
in 1987 (REG87), number of employees in that regulatory department 
in 1987 (EMPR87), regulatory training experience in 1987 (TRN87), 
numher of devices manufactured in 1987 (DEV87), use of regulatory 
consultants in 1987 (CON87), opinion about the impact on time to 
equivalence with regard to oral communication with FDA (OCOMM): 
written communication with FDA (WCOMM), regulatory training 
(TRAIN), in-house regulatory department (INREG), and outside 
regulatory consultants ( OUTREG) • The following estimated regression 
prediction equation was formulated: 
where b 11 b 2 •••• b12 estimate the regression coefficients .B1 , 
Table 17 below highlights the results of this test. 
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Table 17 
Model Relating Variable DAYS TO EQUIVALENCE to 
Multiple Independent Variables 
Multiple R = .787 
variable df Beta Weights p-value 
DAR$ 12 -0.261 O.146 
BJIP087 12 0.113 0.413 
BMPR87 12 0.001 0.987 
RBG87 12 -0.213 0.207 
TRH87 12 -0.036 0.863 
DBV87 12 0.109 O.SC6 
COB87 12 -0.392 0.115 
OC0MM 12 0.652 0.021• 
lfCOMM 12 0.097 0.718 
TRAIN 12 -0.242 0.123 
IHRBG 12 0.176 0.559 
OtrnmG 12 0.701 0.001• 
• Significant at 0.05 level. 
Table 17 represents the calculated beta weights and significance 
levels for each variable. The beta weights were then inserted into 
the multiple regression prediction equation as displayed below. The 
beta weights indicated which variables contributed the most to the 
prediction of days to equivalence, the dependent variable. The 
equation was: 
DAYS '1'0 BQOIVALEHCE • -O.261(YBARS) + 0.113(BNP08?) + 
0.001(EHPR87) + -0.213(RBG87) + -0.036(~87) + 0.109(I>BV87) + 
0.392(COB87) + 0,652(0COMH) + 0.097(WCOMN) + -0.242(~) + 
0.176(:nnmG) + 0.701(00TRBG). 
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The numbers in the equation are interpreted as follows: 
b 1 = -0. 2 61 was the estimate of the relative prediction weight 
for the variable YEARS MANUFACTURING MEDICAL DEVICES~ 
b 2 = 0 .125 was the estimate of the relative prediction weight 
for the variable NUMBER OF EMPLOYEES IN THE ORGANIZATION. 
b 3 = 0.001 was the e&timate of the relative prediction weight 
for the variable NUMBER OF EMPLOYEES IN THE REGULATORY 
DEPARTMENT. 
b, = -0. 392 was the estimate of the relative prediction weight 
for the variable IN-HOUSE REGULATORY DEPARTMENT. 
Estimates were supplied for the remaining population 
parameters (b5 ••• b 12 ) as indicated in the equation above. 
Of i.mpo~~ance were the relative prediction values and 
significance probabilities for the twelve estimates in the multiple 
regression prediction equation. The relative prediction values 
indicated which prediction variables contributed the most to 
successful prediction. The significance probabilities (p-values) 
indicated if the predictor variables were significantly different 
from zero. 
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Review of Table 17 indicates that the respondent's perceived 
influence of outside consultant use on timely compliance and the 
influence of oral communication ~ith FDA en timely compliance were 
the best relative predictors of days to equivalence. Actual use of 
outside regulatory consultants and number of years manufacturing 
medical devices appeared to be secondary contributors to the 
successful prediction of days to equivalence. 
The significance probabilities for the respc•ndent's attitudes 
toward use of outside regulatory consultants and oral communication 
with FDA gave adequate evidence of the statistically significant 
effect of these variables on predicting time to equivalence. 
Furthermore, the p-value at the 0.05 level indicated with 95% 
con£ idence that these particular predictor variables assist in 
decreasing the difference between the predicted and actual 
criterion scores. 
In conclusion, two of the twelve variables were primary 
contributors to successful prediction and two additional variables 
may be considered secondary contributors to successful prediction. 
Opinions about the impact of oral communication .. ,i.th FDA on time 
to equivalence and opinions about the impact of outside regulatory 
consultant use on time to equivalence seemed to best predict time 
to equivalence. Actual use of outside regulatory consultants and 
the m1mher of years a company has been manufacturing medical 
devices were secondary predictors of ti.me to eq-~ivalence. 
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Some suggested conclusions were: 1) regulatory managers who 
perceive outside consultant use as being influential on time to 
equivalence :may expect to have lower mean days to equivalence than 
those managers who disagree with this perception in light of the 
results of testing hypothesis 3. 5: 2) regulatory managers who 
believe that oral communication with FDA does influence timely 
compliance may expect higher mean days to equivalence than those 
managers that do not agree with this tenet in light of the results 
of testing hypothesis 3.2. 
Research Question Number 5 
What variables appear to have an impact on time to equivalence 
as perceived by the company respondent? This research question 
relates to questions number 4 and 10 on the questionnaire. 
Respondents were asked in Question Number 4 their opinion 
about the influence of the FDA review process on production costs. 
Approximately half (54.7%) of the respondents stated that 
production costs were influenced by the FDA review process. When 
examining this same variable within specified subgroups, this same 
distribution was approximated. For example, among companies 
manufacturing more than one device in 1987, 54% stated there was 
an influence on production costs. For companies who received 
regulatory training in 1987, the percentage was 54%. For companies 
who had regulatory departments in 1987, it was 51%. However, among 
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companies who employed regulatory consultants in 1987, 76% stated 
production costs were influenced by the review process. Whereas, 
among companies who did not use outside consultants, only 34% felt 
production costs were influenced by the review process. 
As a result, for the study group as a whole and within many 
subgroupings, opinions were evenly divided with regard to the 
influence of the FDA review process on production costs. However, 
companies that were subgrouped by outside consultant use did not 
follow this pattern. Although companies using outside regulatory 
consultants benefited from this utilization, (i,e., less time to 
equivalence in years immediately following the enactment of a new 
regulation - Hypothesis #2.5), it seemed apparent that it was the 
opinion of companies using outside regulatory consultants that 
production costs were impacted by the FDA review process. In 
contrast, many of the companies that did not use outside 
consultants, did not feel production costs were influeuced by the 
review process. 
With regard to Question Number 10 on the survey, 81% of the 
respondents indicated other things or entities which were not 
directly addressed on the questionnaire that may impact time to 
equivalence. Table 18 below lists those responses and the 
percentage of respondents who emphasized them. 
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Table 18 
Frequency Distribution of Entities 
Impacting Variable TIME TO EQUIVALENCE 
Response Percent 
1) Changing Regulations 26 
2) Changes in FDA Policy 10 
3) Lawyers and FDA Review Panel 10 
4) Limited FDA Staff 10 
5) Properly Prepared Submissions 10 
6) Lack of FDA Funding 4 
7) Pre-clinical Expertise 4 
8) FDA Budget Problems 4 
9) Rapport with FDA 3 
10) Device Complexity 
11) Other 
lla) FDA Overload 
llb) R & D Quality 
2 
~ 
Total = 100 
llc) FDA Reviewer's Knowledge Level 
lld) Binder Quality 
lle) Political Pressure on FDA 
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SUMMARY 
The chapter presented results on the impact of federal social 
regulations upon the time required to establish equivalence for a 
medical device within the orthopaedic medical device industry. 
Means and standard deviations for time to equivalence within 
specified subgroups were calculated. Comparisons of means related 
to company characteristics were made. Regression coefficients and 
Kruskal-Wallis chi-square statistics were calculated. Most relevant 
results of these computations are summarized in the following 
paragraphs. 
Research Question One 
A total of two hundred and sixty three responses was included 
in the data analysis. The impact of federal social regulations upon 
time to equivalence was examined by regressing three independent 
variables on one dependent variable, time to equivalence. 
The first independent variable was the number of years a 
company had been manufacturing medical devices. This impact was in 
a negative direction. A statistically measurable difference was 
detected at the O. 05 level. A relationship was found to exist 
between the number of years manufacturing and time to equivalence. 
As the number of years a company manufactured medical devices 
increased, there was a predictable decrease in the amount of time 
required to get a medical device through the FDA review process and 
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establish equi· llence. 
The secor. ... independent variable was the number of employees 
in the organization. The relationship of this variable with time 
to equivalence was evaluated over time from 1977 to 1987. A 
positive relationship was found to exist from 1978 through 1982. 
As the number of employees in a company increased, so did the 
number of days required to established equivalence during these 
years. 
A statistically significant difference was ascertained at the 
0.05 level from 19713 through 1982, while no predicable relationship 
seemed to exist in 1977, nor from 1983 through 1987. The reason for 
this pattern possibly rests with the combined response of FDA and 
industry to the enactment of the 1976 Medical Device Amendments. 
This represented a maturation process which evolved over time. 
The third independent variable was the number of employees in 
the regulatory department. This relationship was also evaluated 
over time. No statistically significant difference was achieved for 
any year from 1977 through 1987. Although no statistically 
significant difference was apparent, however, the number of 
employees in the regulatory ~apartment did seem to have a negative 
impact on time to equivalence. 
Research Question Two 
The impact cf ~pccified company characteristics on time to 
equivalence was examined. Five independent variables were measured. 
Page 107 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
Time to Equivalence 
Those variables or characteristics were: class of device 
manufactured, in-house regulatory department, regulatory training, 
number of devices manufactured, and use of out-of-house regulatory 
consultants. All variables, but class of device, were evaluated 
over time, 1977 through 1987. A total of 263 responses were 
included in the data analysis. 
For the first independent variable, class of device based on 
the associated degree of risk, the chi-square statistic was not 
statistically significant at the 0.05 level. In other words, time 
to equivalence seemed to be independent of the class of device 
manufactured. 
For the second independent variable, in-house regulatory 
department, the chi-square statistic was found to be statistically 
significant at the 0.05 level in 1979 only. Time to equivalence was 
impacted by the presence of an in-house regulatory department in 
1979, but not from 1977 through 1978, nor from 1980 through 1987. 
The third independent variable, regulatory training, was found 
to impact time to equivalence in 1979 and 1980 only. The chi-
square statis~ic revealed a statistically measurable difference in 
time to equivalence for these years, but not from 1977-1978, nor 
1981 through 1987. Thus, those companies who received regulatory 
training in 1979 and 1980 were found to have a difference in time 
to equivalence at the O .OS significance level as compared to 
companies who did not experience regulatory training in 1979 and 
1980. 
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The fourth independent variable, number of medical devices 
manufactured, influenced time to equivalence for all years except 
1984 and 1986. The chi-square statistic detected a statistically 
measurable difference at the 0.05 level in time to equivalence for 
all years but 1984 and 1986. Aside from 1984 and 1986, companies 
who manufactured more than one device required notably fewer days 
to establish equivalence than companies that manufactured only one 
device. 
For the fifth independent variable, use of an outside 
regulatory consultant had a statistically significant impact on 
time to equivalence from 1977 through 1979, and then again in 1984. 
No difference was detected from 1980 through 1983, nor after 1984. 
The chi-square statistic was statistically significant at the 0.05 
level for 1977, 1978, 1979, and 1983 only. Time to equivalence 
seemed to be dependent on outside consultant use for these years 
alone. 
Research Question Three 
Respondents attitudes about selected attributes of the 
regulatory process and their impact on time to equivalence were 
ex~ined. There were 263 responses in the data analysis. Five 
attributes or independent variables were specified. They were the 
following: oral communication with FDA, written communication with 
FDA, regulatory training, in-house regulatory department, and out-
of-house regulatory consultant use. 
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The chi-square statistic was statistically significant at the 
0.05 level for written communication with FDA and use of outside 
consultants only. No statistically significant difference in class 
means was detected for oral communication with F~":.. regulatory 
training, nor in-house regulatory department. 
Thus, mean values for those respondents who agreed that 
written communication and use of outside consultants impacts time 
to equivalence were statistically different from those respondents 
who disagreed with this tenet. Mean values were significantly lower 
for the respondents who agreed. One reason for this finding may be 
the association of regulatory professionals with regulatory 
compliance. Companies who introduce regulatory professional 
consultants into their organization also introduce increased 
compliance activities (i.e., documentation, record keeping, 
quality control,). FDA inspection is eminent if compliance 
activities are not documented and submitted to FDA. In concert, FDA 
review of medical devices for substantial equivalence is 
facilitated and possibly reduced in time if the agency's 
requirements are fully met on the first submission. 
However, the above resul t.s were suspect based upon the 
measurement process. There was some concern with the reliability 
of the measurement device relati~e to the design of the question 
items on the questionnaire. Although the coefficient of stability 
was satisfactory, the test-retest reliability process had a small 
number of participants (n = 4). Additionally, questions #5 - #9 
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provided possible evidence for the primacy effect. Items presented 
early in the list of options were disproportionately likely to be 
cited among the favored options. Consequently, Questions IS - 9 may 
not have elicited reliable answers. 
Research Question Four 
The impact of federal social regulations on time to 
equivalence was measured by evaluating the combined influence of 
all independent variables differentiated in Research Questions One 
through Three. A total of two hundred and sirty three responses was 
included in the analysis. This equation was formulated to determine 
which population parameters which were converted to beta weights 
best precHcted time to equivalence. 
Thra .multiple regression prediction equation produced beta 
weight estimates which were statistically significant at the 0.05 
level for the opinions about oral communication with FDA and 
opinions about use of outside regulatory consultants. Thus, as 
opinions about oral communication with FDA and its impact on time 
to equivalence shifted from agreeing to disagreeing, there was a 
corresponding increase in days to equivalence. And, as opinions 
about outside consultant use and its impact on time to equivalence 
shifted from agreeing to disagreeing, there was a predictable 
increase in days to equivalence. 
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Research Question Five 
This descriptive analysis accumulated respondent's comments 
about additional things not directly addressed on the surv~y 
questionnaire which the respondent thought influences time to 
equivalence. A total of 263 responses was included in the analysis. 
Eighty one percent ( n = 213) of the respondents provided 
additional entities which they thought impacted the time required 
to get a medical device through the review process and onto the 
market. Sixteen general categories were referenced by the 
respondents. The respondents noted changing regulations as 
impacting time to equivalence most often (26%). The bulk of the 
other comments were represented by the following categories: 
changing FDA policy, lawyers and FDA review panel, limited FDA 
staff, and properly prepared submissions. 
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Chapter V 
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS 
This chapter presents an overview of the study on federal 
social regulations' impacts on time to equivalence in the 
orthopaedic medical device industry. The first section is a review 
of preceding chapters, including discussion of the research problem 
and approach, summary of relevant research literature, method, and 
findings. The conclusion section relates findings to selected 
literature, e.~luates the research and discusses its implications. 
The final section makes recommendations for future study. 
Summary 
The Research Problem 
Research was conducted to evaluate federal social regulations 
and their impact upon the time required to get a medical device 
through the FDA review process and onto the market. Government 
regulation of business can be divided into two basic categories: 
economic and social. The purpose of the study was to investigate 
the degree and nature of impact, due to compliance with different 
categories of the 1976 Medical Device .Amendment, on the ti:::s to 
equivalence for companies with specified characteristics and as 
perceived by the company's regulatory affairs manager. 
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Specifically, the research was designed to answer the 
following research questions: 
1. What is the relationship between time devoted to 
establishing an FDA disposition of substantial equivalence for an 
orthopaedic medical device and related costs and resource 
consumption? 
2. Is there any difference between respondents (companies) 
who possess or do not possess certain identifie& characteristics 
and time required to establish equivalence? 
3. Is there a any difference between time to equivalence and 
respondent's (company's) attitudes about selected characteristics 
of the regulatory process as having an impact on time to 
eq-11i valence? 
4. What combination of independent variable measures best 
predicts time to equivalence? 
5. What variables appear to have an impact on time to 
equivalence as perceived by the company respondent? 
The Research Approaches 
Approach I 
The first level of analysis dealt with Research Question 
Number 1. The research approach was a descriptive-correlational 
survey. Its purpose was to determine the relationship between three 
characteristics of the orthopaedic medical device manufacturing 
company and time to equivalence. 
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Approach II 
The second phase of the analysis addressed Research Questions 
2 and 3. This analysis compared 2 to 5 levels of 10 independent 
variables with one independent variable, 'time to equivalence. Since 
all comparisons involved two or more groups and did not meet the 
assumptions associated with one-way analysis of variance (ANOVA), 
the non-parametric analogue Kruskal-Wallis Test was utilized to 
detect differences between groups or independent variable levels. 
Approach III 
The third method involved the developmeD.t of a multiple 
regression prediction equation with regression coefficients and 
beta weights for all study variables on time to equivalence. This 
was done in an effort to detect which variables best predicted time 
to equivalence. 
Approach IV 
This fourth level of analysis was primarily descriptive. It 
addressed information supplied through questions 4 and 10 on the 
questionnaire. These questions requested the respondent supply 
opinion information. This yielded data which was qualitative in 
nature and nominal on type. 
Criteria for Data Sources 
Several criteria were used to select data sources and include 
the following: 
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Criteria 1. Documents have to be related to orthopaedic medical 
device firms in the United States. 
Criteria 2. Selected device categories have no less than ten 
devices manufactured between 1976 and 1988. 
Criteria 3. Selected firms have a regulatory affairs department and 
manager or some person responsible for regulatory affairs. 
Criteria 4. The person within each firm to whom the request for 
data was addressed was the regulatory affairs manager or person 
responsible for filing SlO(k)s. 
Review of Selected Literature 
The role of government had been primarily to support the 
business system in its role of economic leadership and to mediate 
between business and society. Government's role had changed from 
judging how well business performed its social responsibilities to 
defirting what these responsibilities should be. The role of 
government was enlarged to include a regulatory function. A wave 
of legislative regulation of business followed. The rapid expansion 
of government controls had been associated with a growing 
dissatisfaction with the affects of regulations. 
Two widely accepted divisions of federal government regulation 
were economic and social regulation. Government's basic reform 
strategy had animated the growth of federal protective regulatory 
programs and had created a series of regulatory agencies, all for 
the purpose of bettering and improving, both socially and 
Page 116 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
Time to Equivalence 
economically, the operation of business and industry. Both types 
of regulations cost, as well as benefit, industry and society. 
Weidenbaum (1977) identified expansions of social regulations, 
particularly the six areas of job safety, traffic safety, consumer 
products, personnel justice, consumer finance, and environmental. 
Different regulatory agencies have created guidelines for these 
areas of social regulation. 
Social regulation of the medical industry was first introduced 
in 1938 through the Federal Food, Drug, and Cosmetic Act. Premarket 
approval for a medical device was first required in the late 
1960's. The enactment of 28 bills between 1965 and 1975 culminated 
with the enactment of the Medical Device .Amendments of 1976. 
In addition to the medical device industry, six current 
research studies within regulated industries were reviewed. 
Research approaches were compared with social and econo~ic 
profitability as the focus of the investigations. 
Method 
A descriptive-comparative research approach was conducted to 
examine the relationship and differences between elements of the 
independent variables, company characteristics and opinions, and 
the dependent variable, time to equivalence. Descriptive and 
infere~tial statistical data, characterizing variable relationships 
and differences, were obtained through the use of a mailed survey 
collecting factual and opinion data from a geographically dispersed 
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population of orthopaedic medical device manufacturers. A 
researcher-designed questionnaire was used to collect data. A 
descriptive-comparative approach was used for data analysis. 
Collection of Data 
Data sources for the study were small and large orthopaedic 
medical device manufacturers from all over the U.S. Firms were 
selected from the SlO(k) Register, which listed all SlO(k) device 
submissions from 1976 to 1987. There were 263 usable responses from 
firms representing 27 different device categories. 
The researcher-designed instrument consisted of a letter of 
transmittal and a questionnaire composed of three data collection 
pages with instructions. 
After meeting criteria for data sources, steps were taken to 
implement data collection. The questionnaire was mailed to small 
and large firms selected from the 510lk) Register. Responses to the 
questions were compiled on an individual basis. A total of 106 
questionnaires with self-addressed envelops was mailed. This 
process resulted in a 23% return rate. Those respondents who did 
not return the mailed survey initially were then surveyed via the 
telephone. These two combined techniques produced a total of 39 
companies with a 47.5% return rate. 
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Analvsis of Data 
Descriptive-comparative statistics were used to answer the 
research questions. Standard measur~s of central tendencies 
comprising means and standard deviations were used to describe 
relationships and differences between variables. Analyses for the 
impact of the independent variables upon the dependent variable, 
time to equivalence, were performed. Comparisons of means related 
to company characteristics were made. Regression coefficients, beta 
weights and Kruskal-Wallis chi-square statistics were calculated. 
Findings 
Research Question One asked what was the relationship between 
time devoted to establishing an FDA disposition of substantial 
equivalence for an orthopaedic medical device and related costs and 
resource consumption. 
Hypothesis 1.1. The first independent variable was the number 
of years a company had been manufacturing medical devices. This 
impact was in a negative direction. A statistically significant 
di£ ference was detected at the O. OS level. A relationship was found 
to exist between the number of years manufacturing and time to 
equivalence. As the number of years a company manufactured medical 
devices increased, there was a predictable decrease in the amount 
of time required to get a medical device through the FDA review 
process and establish equivalence. 
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Hypothesis 1. 2. The second independent variable was the number 
of employees in the organization. The relationship of this variable 
with time to equivalence was evaluated over time from 1977 to 1987. 
Positive relationships were found to exist from 1978 through 1982. 
As the number of employees in a company increased, so did the 
number of days required to establish equivalence during these 
years. 
A statistically significant difference was ascertained at the 
0.05 level from 1978 through 1982, while no predicable relationship 
seemed to exist in 1977, nor from 1983 through 1987. 
A rationale for this result may be found in the combined 
response of FDA and industry to the enactment of the 1976 Medical 
Device Amendments. The years immediately following the enactment 
brought about many changes in personnel and resource consumption 
for both the agency and industry. As years passed the FDA review 
process became more competent and sophisticated. Companies employed 
increasingly more professionals to meet the increased FDA 
compliance stipulations. However, companies discovered that 
saturated departments were not producing reduced time to 
equivalence. 
Hypothesis 1.3. The third independent variable was number of 
employees in the regulatory department. This relationship was also 
evaluated over time. No statistically significant difference was 
achieved for any year from 1977 through 1987. Although no 
statistically significant difference was apparent, the number of 
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employees in the regulatory department did seem to have a negative 
impact on time to equivalence. 
Research Question Two asked if there lA.-ere any differences 
between respondents (companies) who possess or do not possess 
certain identified characteristics and time required to establish 
equivalence. 
Hypothesis 2.1. For the first independent variable, class of 
device based on the associated degree of risk, the chi-square 
statistic of 0.224 was not statistically significant at the 0.05 
level. In other words, time to equivalence seemed to be independent 
of the class of device manufactured. 
Hypothesis 2.2. For the second independent variable, in-house 
regulatory department, the chi-square statistic of 4.11 was found 
to be statistically significant at the 0.05 level in 1979 only. 
Time to equivalence was impacted by the presence of an in-house 
regulatory department in 1979, but not from 1977 through 1978, no~ 
from 1980 through 1987. 
Hypothesis 2.3. The third independent variable, regulatory 
training, was found to impact time to equivalence in 1979 and 1980 
only. The chi-6quare statistic of 7.04 in 1979 and 1980 revealed 
a statistically measurable difference in time to equivalence for 
these years, but not from 1977-1978, nor 1981 through 1987. Thus, 
those companies who received regulatory training in 1979 a..~d 1980 
were found to have a difference in time to equivalence at the 0.05 
significance level as compared to companies who did not experience 
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regulatory training in 1979 and 1980. 
Hypothesis 2.4. The fourth independent variable, number of 
medical devices manufactured, influenced time to equivalence for 
all years except 1984 and 1986. The chi-square statistic detected 
a statistically measurable difference at the 0.05 level in time to 
equivalence for all years but 1984 and 1986. The chi-square 
statist.ic of 11.60 from 1977 through 1979 was noteworthy. Aside 
from 1984 and 1986, companies who manufactured more than one device 
required notably fewer days to establish equivalence than companies 
that manufactured only one devi~c" 
Hypothesis 2.5. For the fifth independent variable, use of an 
outside regulatory consultant had a statistically significant 
impact on time to equivalence from 1977 through 1979, and then 
again in 1984. No difference was detected from 1980 through 1983, 
nor after 1984. The chi-square statistic for 1977 ( 5 .17), 1978 
(6.02), 1979 (7.18) and 1983 (4.47) was statistically significant 
at the 0.05 level. Time to equivalence seemed to be dependent on 
outside consultant use for tnese years alone. 
Research Question Three asked if there were any differences 
between time to equivalence and respondent's (company's) attitudes 
about selected characteristics of the regulatory process as having 
an impact on time to equivalence. 
Hypothesis 3. 1. The first independent variable, written 
conanunication with FDA, was measured. The chi-square statistic of 
15.67 was statistically significant at the 0.003 le~el indicating 
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that those respondents who agreed with the tenet that written 
cODDDUnication with the FDA has an impact on time to equivalence had 
a significantly lower mean days to eq-.ii valence than those that 
disagreed with this position. 
Hypothesis 3.2. The second independent variable, oral 
communication with FDA, was evaluated. No statistically significant 
difference was detected in mean responses to this variable. The 
number of days required to get a device through the FDA review 
process seemed to be independent of respondents' opinions about 
oral communication with FDA. 
Hypothesis 3 • 3 • The third independent variable, opinions about 
regulatory training, was evaluated with regard to time to 
equivalence. The difference in mean days to equivalence for 
respondents who agreed or did not agree that regulato:?:'y training 
impacted time to equivalence was not statistically significant. 
Hypothesis 3.4. The fourth independent variable, opinions 
about the presence of an in-house regulatory department and its 
impact on the FDA review process, was evaluated. No statistically 
significant difference at the 0.05 level in mean days to 
equivalence was detected betwe~~ "t!la classes of agreement, although 
the vast majority of the respondents agreed that time to 
equivalence was impacted by the presence of an in-house regulatory 
department. 
Hypothesis 3. 5. The fifth independent variable, opinions about 
regulatory consultant use and its impact on time to equivalence, 
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was measured. The chi-square statistic of 11.25 was statistically 
significant at the 0.024 level of significance. This would seem to 
suggest that those respondents who agreed with the tenet that 
consultant use impacts time to equivalence had a statistically 
measurable difference in mean days to equivalence from those that 
did not agree. Those respondents who agreed h_ad lower mean days to 
equivalence than those who did not agree. 
Question Number Four asked what combination of independent 
variable measures best predicted time to equivalence. 
Multiple regression prediction converted beta weights were 
statistically significant at the O. 05 level for opinions about oral 
communication with FDA and opinions about use of outside regulatory 
consultants. Thus, as opinions about oral communication with FDA 
and its impact on time to equivalence shifted from ·agreeing to 
disagreeing, there was a corresponding increase in days to 
equivalence. And, as opinions about outside consultant use and its 
impact on time to equivalence shifted from agreeing to disagreeing, 
there was a predictable increase in days to equivalence. 
Question Number Five asked what variables appeared to have an 
impact on time to equivalence as perceived by the company 
respondent. 
Eighty one percent {n = 213) of the respondents provided 
additional entities which they thought impacted the time required 
to get a medical device through the review process and onto the 
market. Sixteen general categories ~--ere referenced by the 
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respondents. The respondents noted changing regulations as 
impacting time to equivalence most often (26%). The bulk of the 
other comments were represented by the following categories: 
changing FDA policy, lawyers and FDA review panel, limited FDA 
staff, and properly prepared submissions. 
Conclusions 
This section discusses conclusions drawn from the findings, 
relates them to prior research, and presents implications of the 
findings regarding business and government. The research addressed 
the relationship of federal social regulations and the time 
required to get an orthopaedic medical device through the FDA 
review process and onto the market for commercial distribution. 
Financial profit and performance of medical device firms, measured 
by time to equivalence, was generally impacted by some, but not 
all, company characteristics in conjunction with federal social 
regulations. The degree of influence was tempered by circumstances 
surrounding the industry and the agency at the time of the 
evaluation. As the 1976 Amendments unfolded in the first few yea:t·s, 
both industry and federal agency influenced time to equivalence. 
This dynamic pericd had general ~~sitive and negative effects on 
time to equivalence. When company characteristics were examined 
separately over time, specific positive and negative influences 
could be perceived. 
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Of the three variables relating costs and resource consumption 
to time to equivalence, the number oi years a company manufactured 
medical devices tended to negatively influence time to equivalence 
the greatest. The number of employees in the organization increased 
time to equivalence during the early years of the amendment 
enactment, but had little effect in the later years. The number of 
employees in the regulatory department had very little influence 
on time to equivalence, al though e gradual decline in time to 
equivalence was seen year after year with regard to this variable. 
Of the five identified company characteristics proposed to 
have an influence on time to equivalence, companies that 
manufactured more than one device had the most consistent 
difference in mean days to equivalence over time. The type of 
device a company manufactured had little impact on time to 
equivalence. The presence of an in-house regulatory department had 
some influence on the mean days to equivalence, but this was in the 
years just after the enactment of the 1976 amendment. Regulatory 
compliance training also had an impact on time to equivalence, but 
this was only observed in 1979 and 1980 when federal guidelines 
related to the 1976 amendment were being better explicated and 
interpreted by both industry and agency. Use of regulatory 
consul tan ts impacted time to equivalence, but only in selected 
years. In the early years after the 1976 amendment enactment when 
the guidelines were least understood and most difficult to 
implement, consultant use was highest and seemed to have the 
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greatest influence on time to equivalence. Then again in 1984, when 
new, additional guidelines were issued, consultant use appeared to 
produce a difference in mean days to equivalence. 
Of the five selected respondents' (companys') attitudes about 
specified characteristics of the regulatory process, the different 
classes of agreement regarding written communication with FDA and 
use of out-of-house consultants were most dissimilar. The data were 
generally sufficient to indicate a difference in mean time among 
the different categories of agreement. The respondents' differen~ 
categories of opinion with respect oral communication with FDA, 
regulatory compliance training, and the existence of an in-house 
regulatory department were not apparently different as they related 
to mean days to equivalence. 
The variability of relative prediction estimates was great for 
the twelve combined independent variables. Opinions about use of 
outside consultants and oral communication with FDA best predicted 
time to equivalence. A relationship was seen to exist between these 
variables and time to equivalence. Based on the classification 
system, opinions which favored consultant use and oral 
communication with the FDA also corresponded with a decrease in 
time to equivalence. However, the aggregation of data as to what 
the combined effect these selected independent variables had on 
time to equivalence was difficult to determine. 
Financial profits and performance are vital elements in the 
success of the business operation. As such, the influence of social 
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regulation upon financial profits and perfoJ:111anca has an ;mportant 
impact in this area. Conclusions that there exists a clear 
relationship between business and government, that the relationship 
sometimes benefits business operations, and at other times hinders 
the growth of the business, can be applied to social regulation as 
well. 
While realizing that positive, negative, and no influence 
relationships exist, a general statement on the impact of 
regulations and company characteristics on time to equivalence can 
be drawn from the research findings. The conclusion is that the 
general impact of social regulation and selected company 
characteristics upon time to equivalence for small and large 
orthopaedic medical device manufacturers is negative at a minor 
level. 
Of the many arguments in the literature favoring social 
responsibility, the most prevalent was that of the long-run self-
interest of business. This concept rationalizes that society 
expects business to be aware and consider the needs and goals of 
society in the internal decision process if business expects to 
profit in the long run. The argument is actually a sophisticated 
concept of long-run profit maximization, i.e., spending money to 
comply with socially imposed guidelines will result in more profit 
for business. Assuming that decreased time to equivalence results 
in reduced compliance costs, the literature by Ford (1969) and the 
tentative results of prior studies suggesting that socially 
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responsible firms :may be more profitable were supported by the 
present study. 
Implications for Business and Government 
The development of social regulations in American business has 
.been brought about by both external and internal events. External 
causes have been largely legislative in nature. 
Federal social regulations, through their impact upon profit 
and performance of small and large firms, have impact of great 
significance upon business and government decision making and 
policy formation in general. A management philosophy which includes 
both pragmatic and idealistic aspects often presents management 
with a troublesome dilemma. On the one side, business management 
must pursue economic objectives; on the other, they must undertake 
social objectives. Management must attempt to resolve this dilemma. 
In support of economic objectives, if a business firm fails 
to make a profit, the firm will not survive. Should this happen, 
the firm will be in no position to assume social objectives. 
However, this is an extremely polar view of the dilemma. In 
reality, it is not so easy to separate economic objectives from 
social ones. 
Understanding the particular impacts to be expected from 
social regulations and how they relate to financial profit and 
performance is crucial to private enterprise in their internal 
decision making regarding the policy and strategy formulation of 
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their overall business operation. A major implication in preceding 
studies was the possibility of a business-government coalition. It 
is essential for the government sector to understand and take into 
account the impact of their decision making and imposition of 
regulations. To effectively weigh costs and benefits of legislation 
requires knowledge of its impact. This has implications for medical 
device manufacturers and regulatory consultants. The ability to 
determine when to implement the expertise of a regulatory 
consultant or expand a regulatory department may have dramatic 
results on market emergence. This study suggests that regulatory 
expertise should be sought within the first two years of new 
regulation enactment since the effects of compliance related 
activities are most dramatic during this period. It should also be 
emphasized that a regulatory consultant or regulatory department 
encompass many individuals with varied expertise. The consultive 
team of physicians, statisticians, nurses, and lawyers in concert 
with the regulatory professional is needed to truly effect time to 
equivalence within the medical device industry. 
Attempts to stimulate the economy through an increase in 
financial profit and perfonnance must take into account current 
policies that work as restraints. The study identified major 
company characteristics which interact with these restraints which 
impact operations of orthopaedic medical device firms. 
Social regulations do open up certain opportunities of which 
companies can take advantage. The varied impact of social 
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regulations in relation to orthopaedic medical devices indicates 
the complexity of the impact structure and negates efforts to 
formulate effective broad-based regulatory legislation. 
Firms which fail to recognize the importance of social issues 
and drag their feet on positive action or attempt to side step 
federally sanctioned guidelines are facing not only public and 
government action, but, more importantly, severe delays in entering 
a very competitive market. Battle lines are drawn and the challenge 
is clear. Only the future can tell what the outcome will be. 
The results of this specific study suggested that medical 
device manufacturers and possibly other similar companies may 
negatively influence the time required by FDA to review a Sl0(k) 
submission by doing the following: 
1) Engage regulatory professional consultants when new 
regulations which are difficult to interpret by in-house 
personnel are introduced or when repeated deficiency 
letters are returned from FDA. 
2) Expect your regulatory affairs consultant to be an expert 
in clinical protocol and designs monitoring. 
3) If training provided by sanctioned regul~tory bodies is 
not satls£actory, engage consultants to provide training 
to company pe~sonriel in new developments in procedures 
which are sensitive to your medical device. 
4) Increase the scientific sound.TJ.ess of the submissions 
since FDA is continually increasing its regulatory 
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requirements. 
5) Communicate, both orally and in writing, with FDA when 
device configuration or indication changes are 
introduced. 
6) New companies within the medical device industry should 
make early investments in regulatory expertise since time 
to equivalence declines with an increase in experience 
(i.e., number of years manufacturing) and a 
diversification of product (i.e., number of devices 
manufactured) • 
7) In the future, possibly consider industry self-regulation 
with minimal FDA oversight. 
Recommendations for Future Research 
This was a descriptive-comparative study which evaluated the 
impact of social regulations in conjunction with selected company 
characteristics on orthopaedic medical device manufacturer's 
ability to reduce the time to reach substantial equivalence with 
a pre 1976 amendment medical device as determined by FDA reviewers. 
The study suggested several areas for additional research, 
concerning many of the same variables and issues. Therefore, 
several expanded studies were recommended as follows: 
1. Expand the current study to include a statistically 
significant number of medical device firms other than orthopaedic. 
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This recommendation was supported by this study' s questionable 
generalization. 
2. Expand the current study to include other company and 
agency characteristics in the evaluation of a medical device firm's 
profitability. This was supported by the logical projection of this 
current study. 
3. Expand the current study to include the impact of company 
characteristics and regulations upon other areas of profitability 
(i.e., marketing, manufacturing, finance, etc.) relevant to gross 
income. This also appeared to be a natural projection of this 
study's endeavors. 
4. Further research defining and clarifying the impact, 
particularly positive contributions of regulation, that is needed 
to assist in effective planning and decision making by bus~ness and 
government. This recommendation was guided by the need for an 
alternative orientation to evaluating the impact of regulations, 
since this study was basically negative in perspective. 
5. Further research should be done using a larger sample. 
As with any experimental design and analysis, more confident 
inferences can be made and conclusions drawn when the study sample 
more approximates the study population. 
6. Expand the study to represent both large and small firms 
equally and analyzed separately. This also would. further generalize 
the study results. 
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7. Develop a study to include only Class III devices since 
there are more profitability measures associated with this mora 
risk related device. 
8. Develop a study which clearly confirms the connection 
between social regulations and profit and performance. This 
recommendation was based on the l~terature supported need for such 
analysie. 
9. Develop a study to educate medical device manufacturers 
about the most efficient and cost effective paths to regulatory 
compliance. This recoJIDDendation was apparent in view of this 
study's finding that reg-~latozy training seemed have little impact 
on time to equivalence. 
10. Design a study to ds~elop the reliability and validity 
of the measurement in.strument. This r~~ommendation was based on the 
need for a more ac~urate and standardized data collection vehicle. 
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APPENDIX A 
Director, Regulatory Department P.O. :Sox 988 
O. S. Highway 30 East 
Warsaw, IN 46S80 
Dear Director, 
In conjunction with the University of San Diego, I am conducting research in the field of regulatory affairs and medical devices. Part of the initial stages of the research requires a pilot study. Its purpose is to assess the viability and feasibility of the proposed study. One of the main tasks of this pilot is the assessment of the data collection form or questionnaire. 
Please find enclosed a copy of the questionnaire that will be mailed to approximately 250 regulatory affairs managers such as yourself. These managers will be from throu,qho\tt ~·!e U.S. Along with the questionnaire, the regulatory affairs manager will receive a cover letter explaining the research project. You have a copy of this as well. · 
I fully appreciate your very busy schedule, but your assistance is needed in the validation process of this questionnaire. Would you take 20-30 minutes to review the enclosed cover letter and questionnaire? Some of the areas which I would like you to address are: l) Is the questionnaire realistic? 2) Will managers fill it out? 3) Do the questions address the issue of compliance and the time needed to get a device through the SlO(k) process? 4) Are there questions which might compromise the company? 5) Does the cover letter invoke a feeling of cooperation which would help secure the participation of the manager in the study? 
Your comments are essential to the success of this project. Please feel free to write directly on the cover letter and questionnaire. Once finished, please return the docume,1ts in the self addressed Federal Express overnight envelop included here. 
A preliminary pul:)lishing agreement has been reached with a journal interested in the results of this study. Your comments and contributions will make this project that much more relevant. 
Thaz,Jc you for your time and cooperation. Hopefully, our ef fori:s may produce a document which may facilitate the SlO(k) process and save medical device manufactu:ers money and resources. 
Sincerely, 
John J. Carlow 
Director, Clinical Statistics 
JJC/mdg 
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APPENDIX B 
Supervisor - Clinical/Regulatory Affair 3M Company 
3M Center 270-SN-05 
St. Paul, MN 55144 
:,ear Ms. Danielson, 
Research is being conducted en the impact of government regulations upon the time required to get an orthopaedic medical device through the FDA review process and onto the market. Your firm was selected through publication of the SlOlk) Register. You met the selection criteria because your co~panyhas had at least one product approved th.rough the SlO(k) proces~ between the years 1977-1987 • . The key role you have in your fixm's success makes your view and ,:ounsel of extreme value. Would ycu please contribute to this research by completing the enclosed q,~estionnaire. 
The questionnaire is designed to obtain specific information about your company. In addition, your opinion on the impact of federal regulation upon your firm's ability to successfully progress through the premarket notification process is also being requested. 
Recognizing your demanding schedule, the form was designed to be completed in a minimum of time. If, after completing the questionnaire, you desire a summary copy of the research results, please indicate so on the form. Results are expected to be mailed in !'.ay, 1990. 
If you so choose, you do not have to participate in this research project. However, if you choose to participate by completing the questionnaire, you are not required to answer questions you feel may be compromising to you or your company. 
The information you contribute to th.is research will remain confidential and be used only to support this study. 
It is essential that your response be received by September, 1989. Your contribution, by completing the enclosed questionnaire, will add .immensely to the knowledge in this area. 
Th~&k you for your time and interest. 
Sincerely1 
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APPENDIX C 
SURVEY QUESTIONNAIRE 
l.O Please indicate the yeu your ccmpany started manu:acturing medical devices? 




















__ Yes _No 
__ Yes _No 
_Yes _No 
__ Yes __ No 
_Yes __ No 
__ Yes _No 
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APPEEDIX C ( continued) 












Were you Manufacturing 




__ Yes _No 
_Yes _No 
_Yes __ No 
_Yes __ No 
__ Yes __ No 
_Yes _No 
__ Yes _No 
_Yes __ No 
Did your Department 
Receive Regulatory 




_Yes __ No 
_Yes _No 
_Yes __ No 
__ Yes _No 
_Yes _No 
_Yes __ No 
_Yes __ No 
_Yes _No 
4.0 In you: opinion, are production costs influenced by the time requi.red to get a device through the review procetss and onto the ma:ket. _Yes _No. If y<!s, please explain. 
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APPENDIX C (continued) 
Please indicate your PER.CBPTION of the kind of in£luence the following events or situations have PRESENTLY on the time that is needed to get a product th:ough the FOA review process and to the market. Ci:cle the appropriate category that describes your perception for questiorui 4 through 8 below. 



































~.0 In your opinion, are thsre other things wnich impact the time to get a product through t~e rsview process and onto the market? 
If you want the results of th.is r9search forwarded to you, please indicate l)y checkinq the appropriate catego:y. _Yes _No 
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APPENDIX D 
Snmmary of Research Hypotheses Regarding the Relationship Between Organizational Characteristics and Time to Established Equivalence 
~IONSHIP 
Hypothesis Dependent Inde'Cendent Expected Direction Number Va:iable Variable of the Relationsnip 
1.1 Time (days) to Number of Yea.rs Equivalence. manufacturing Negative Medical Devices 
1.2 Till:e (days} to NUlnber of Equivalence. Employees in Negati,re v;..;ci.g-cm.ization 
l.3 Time (d.ays) to NUlnber of Equivalence. E:.n.ployees in Negative Regulatory 
Depa.rt:11en1: 
Page 150 
Reproduced with permission of the copyright owner.  Further reproduction prohibited without permission.
APPENDIX E 
Summary of Research Hypotheses Rega:ding The Difference Bet-~~ Company Chartacteristics and. Timely Compliance 
COMPARISON 
Hypothesis Dependent Independent Significance Numl:)er Variable Va:ia.ble Level a a.OS 
2.l Time (days) to Type of 
Equivalence. Device Significance Manufactured. Level a a.OS 
2.2 Time (days) to In-a:ouse 
Equivalence. Regulatory Significance Department Level = a. 05 
2.3 Time (d.ays) to Regulatory 
Equivalence. Compliance Significance Training Level= a.as 
2.4 Time ( ciays) to Numl:)er of 
Equivalence. Devices Significance Manufactured. Level :a a.as 
2.5 Time ( ciays) to Use of Outside 
I 
:6:q-.:i valc:nce • Regulatory Significance Consultants Level= a.as 
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I 
APPENDIX 'Z 
Summary of Research H7POtheses Regarding 
Differences in Top Executives Perceived Influences 
on Timely Ccmpliance and Time to Equivalence 
COMPARISON 
Bn,othe~is Dependen-e Independent Significance 
Nmnber Va.:iable Variable Level 
3.l Time (days) to FDA 
Equivalence. Written Significance 
Communication Level= a.as 
3.2 Time (days) to FDA 
Equivalence. Cral Significance 
Communication Level 2 0.05 
3.3 Time (days) to OSMA/Regulatory 
E;_1li valence. T:raining Significance 
Level= a.as 
3.4 Time (days) to In-Bouse 
Equivalence. Regulatory Significance 
Department Level 2 a.as 
3.5 Time (days) to Outside 
Equivalence. Regulatory Significance 
Consultants Level• 0.05 
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